###begin article-title 0
Association of warfarin dose with genes involved in its action and metabolism
###end article-title 0
###begin p 1
###xml 558 621 558 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1, CYP2C9, CYP2C18, CYP2C19, PROC, APOE, EPHX1, CALU, GGCX</italic>
###xml 626 635 626 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1-ORM2</italic>
###xml 654 718 654 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1, CYP2C9, CYP2C8, CYP2C19, PROC, F7, GGCX, PROZ, F9, NR1I2</italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1</italic>
###xml 728 732 728 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM2</italic>
###xml 760 761 760 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 771 794 771 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1, CYP2C9, CYP2C18</italic>
###xml 799 806 799 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 879 880 879 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 922 929 922 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 934 941 934 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 993 1001 993 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 1009 1011 1009 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 1013 1017 1013 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 1022 1026 1022 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 1140 1160 1140 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1, CYP2C9, PROC</italic>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
We report an extensive study of variability in genes encoding proteins that are believed to be involved in the action and biotransformation of warfarin. Warfarin is a commonly prescribed anticoagulant that is difficult to use because of the wide interindividual variation in dose requirements, the narrow therapeutic range and the risk of serious bleeding. We genotyped 201 patients for polymorphisms in 29 genes in the warfarin interactive pathways and tested them for association with dose requirement. In our study, polymorphisms in or flanking the genes VKORC1, CYP2C9, CYP2C18, CYP2C19, PROC, APOE, EPHX1, CALU, GGCX and ORM1-ORM2 and haplotypes of VKORC1, CYP2C9, CYP2C8, CYP2C19, PROC, F7, GGCX, PROZ, F9, NR1I2 and ORM1-ORM2 were associated with dose (P < 0.05). VKORC1, CYP2C9, CYP2C18 and CYP2C19 were significant after experiment-wise correction for multiple testing (P < 0.000175), however, the association of CYP2C18 and CYP2C19 was fully explained by linkage disequilibrium with CYP2C9*2 and/or *3. PROC and APOE were both significantly associated with dose after correction within each gene. A multiple regression model with VKORC1, CYP2C9, PROC and the non-genetic predictors age, bodyweight, drug interactions and indication for treatment jointly accounted for 62% of variance in warfarin dose. Weaker associations observed for other genes could explain up to approximately10% additional dose variance, but require testing and validation in an independent and larger data set. Translation of this knowledge into clinical guidelines for warfarin prescription will be likely to have a major impact on the safety and efficacy of warfarin.
###end p 1
###begin title 2
Electronic supplementary material
###end title 2
###begin p 3
Supplementary material is available in the online version of this article at  and is accessible for authorized users.
###end p 3
###begin title 4
Background
###end title 4
###begin p 5
###xml 206 210 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2003</xref>
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">1993</xref>
###xml 640 644 640 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2001</xref>
###xml 668 672 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2003</xref>
###xml 690 694 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">2004</xref>
Warfarin is one of the most widely used coumarin anticoagulants in the treatment of atrial fibrillation, heart valve prosthesis, recurrent stroke, deep vein thrombosis and pulmonary embolism (Daly and King 2003). However, its use is made difficult by the wide interindividual variation in dose required to achieve a therapeutic effect, the narrow therapeutic range, and the risk of serious bleeding (Landefeld and Beyth 1993). Warfarin dose requirement, which varies 20-fold, is influenced by factors such as intake of vitamin K, ethnicity, illness, age, gender, concurrent medication, body mass index and genetic factors (Loebstein et al. 2001; Takahashi and Echizen 2003; Wadelius et al. 2004).
###end p 5
###begin p 6
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">1972</xref>
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2005</xref>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 445 449 445 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR69">2006</xref>
###xml 526 532 526 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 544 548 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2004</xref>
###xml 562 566 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">2004</xref>
###xml 595 601 595 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 690 694 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2005</xref>
###xml 710 714 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2005</xref>
###xml 730 734 730 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">2005</xref>
###xml 750 754 750 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">2005</xref>
###xml 772 776 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">2005</xref>
###xml 794 798 794 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">2005</xref>
###xml 812 816 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">2005</xref>
###xml 929 934 929 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EPHX1</italic>
###xml 934 935 934 935 <bold xmlns:xlink="http://www.w3.org/1999/xlink">,</bold>
###xml 997 1001 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1997</xref>
###xml 1020 1024 1020 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2005</xref>
###xml 1048 1052 1048 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2005</xref>
###xml 1077 1081 1077 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALU</italic>
###xml 1171 1175 1171 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR61">2001</xref>
###xml 1190 1194 1190 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">2004</xref>
###xml 1197 1203 1197 1203 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1203 1438 1203 1438 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="7">An overview of the interaction between warfarin and the 29 genes. This pathway illustrates genes thought to mediate the effects of warfarin. It also depicts a simplified representation of the biotransformation of warfarin and vitamin K</p>
###xml 1203 1438 1203 1438 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="7">An overview of the interaction between warfarin and the 29 genes. This pathway illustrates genes thought to mediate the effects of warfarin. It also depicts a simplified representation of the biotransformation of warfarin and vitamin K</p></caption>
###xml 1438 1438 1438 1438 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="439_2006_260_Fig1_HTML" id="MO1"/>
###xml 1197 1438 1197 1438 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="7">An overview of the interaction between warfarin and the 29 genes. This pathway illustrates genes thought to mediate the effects of warfarin. It also depicts a simplified representation of the biotransformation of warfarin and vitamin K</p></caption><graphic position="anchor" xlink:href="439_2006_260_Fig1_HTML" id="MO1"/></fig>
###xml 589 594 <span type="species:ncbi:9606">human</span>
Warfarin acts through interference with the recycling of vitamin K in the liver, which leads to secretion of inactive vitamin K-dependent proteins (Bell et al. 1972; Dahlback 2005). Figure 1 shows the genes that are believed to be involved in the biotransformation of vitamin K, warfarin and the vitamin K-dependent clotting factors, here called the warfarin interactive pathways (Supplementary Table S1; for details see Wadelius and Pirmohamed 2006). The main protein in the vitamin K epoxide reductase complex is encoded by VKORC1 (Li et al. 2004; Rost et al. 2004). Common variation in human VKORC1 is one of the most important genetic factors determining warfarin dose (D'Andrea et al. 2005; Geisen et al. 2005; Rieder et al. 2005; Sconce et al. 2005; Wadelius et al. 2005; Veenstra et al. 2005; Yuan et al. 2005). Another putative subunit of the vitamin K epoxide reductase is the microsomal epoxide hydrolase 1, encoded by EPHX1, which harbours a vitamin K-epoxide binding site (Cain et al. 1997; Loebstein et al. 2005; Morisseau and Hammock 2005). Calumenin, encoded by CALU, binds to vitamin K epoxide reductase and inhibits the effect of warfarin (Wallin et al. 2001; Wajih et al. 2004). Fig. 1An overview of the interaction between warfarin and the 29 genes. This pathway illustrates genes thought to mediate the effects of warfarin. It also depicts a simplified representation of the biotransformation of warfarin and vitamin K
###end p 6
###begin p 7
An overview of the interaction between warfarin and the 29 genes. This pathway illustrates genes thought to mediate the effects of warfarin. It also depicts a simplified representation of the biotransformation of warfarin and vitamin K
###end p 7
###begin p 8
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 89 90 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2004</xref>
###xml 299 300 299 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 341 345 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 378 380 378 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2</italic>
###xml 384 386 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E3</italic>
###xml 389 392 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*E4</italic>
###xml 407 411 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">1993</xref>
###xml 430 434 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">1996</xref>
###xml 639 643 639 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">1982</xref>
###xml 663 667 663 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2004</xref>
A high intake of the fat-soluble vitamin K1 can reverse the action of warfarin. Vitamin K1 is absorbed from the small intestine along with dietary fat, and subsequently cleared by the liver through an apolipoprotein E (APOE) receptor specific uptake (Berkner and Runge 2004). The uptake of vitamin K1 into the liver varies between different APOE alleles and is in the order of *E2 < *E3 < *E4 (Saupe et al. 1993; Kohlmeier et al. 1996). It has also been suggested that the antioxidant enzyme nicotine adenine dinucleotide phosphate (NAD(P)H) dehydrogenase, encoded by NQO1, has the potential to reduce dietary vitamin K (Wallin and Hutson 1982; Berkner and Runge 2004).
###end p 8
###begin p 9
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX</italic>
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR64">1997</xref>
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2000</xref>
###xml 326 360 326 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2, F7, F9, F10, PROC, PROS1, PROZ</italic>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAS6</italic>
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2004</xref>
###xml 483 491 483 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERPINC1</italic>
###xml 557 561 557 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2005</xref>
###xml 621 623 621 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 730 734 730 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1998</xref>
Reduced vitamin K is the essential cofactor for the activation of vitamin K-dependent proteins by gamma-glutamyl carboxylase, encoded by GGCX (Wu et al. 1997; Berkner 2000). The main vitamin K-dependent proteins are clotting factors II, VII, IX and X, proteins C, S and Z, and the growth-arrest specific protein 6, encoded by F2, F7, F9, F10, PROC, PROS1, PROZ and GAS6, respectively (Berkner and Runge 2004). A non-vitamin K-dependent clotting protein anti-thrombin III, encoded by SERPINC1, inhibits the vitamin K-dependent factors II, IX and X (Dahlback 2005). Furthermore, the point mutation Arg506Gln (FV Leiden) in F5 is a common cause of thromboembolism, and is therefore a known cause of warfarin treatment (Larsen et al. 1998).
###end p 9
###begin p 10
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2005</xref>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">1992</xref>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">1996</xref>
###xml 472 476 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1</italic>
###xml 481 485 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM2</italic>
###xml 502 506 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">1987</xref>
###xml 586 587 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 587 590 587 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
###xml 619 623 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">1992</xref>
###xml 644 648 644 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1997</xref>
###xml 665 671 665 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 688 690 688 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 695 697 695 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 796 798 796 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1</italic>
###xml 922 926 922 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2005</xref>
###xml 1034 1038 1034 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">1992</xref>
###xml 1059 1063 1059 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1997</xref>
###xml 1135 1139 1135 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">1992</xref>
###xml 1154 1158 1154 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR66">1995</xref>
###xml 1179 1183 1179 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1997</xref>
###xml 1306 1310 1306 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">1992</xref>
###xml 1325 1329 1325 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR66">1995</xref>
###xml 1350 1354 1350 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1997</xref>
###xml 1369 1373 1369 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2004</xref>
###xml 1387 1388 1387 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1388 1391 1388 1391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
###xml 1536 1541 1536 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR1I2</italic>
###xml 1546 1551 1546 1551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR1I3</italic>
###xml 1568 1572 1568 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">1998</xref>
###xml 1586 1590 1586 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2004</xref>
###xml 1763 1768 1763 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1</italic>
###xml 1770 1774 1770 1774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1792 1796 1792 1796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2002</xref>
###xml 1879 1883 1879 1883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2001</xref>
###xml 651 659 <span type="species:ncbi:9606">Patients</span>
The molecular basis of warfarin pharmacokinetics has been extensively studied (Sanderson et al. 2005). Warfarin is administered as a racemate that consists of R- and S-enantiomers, the S-form being 3-5 times more active than the R-form (Rettie et al. 1992). Warfarin is rapidly absorbed from the stomach and the upper gastrointestinal tract (Palareti and Legnani 1996), and in the circulating blood it is highly bound to albumin and alpha 1-acid glycoproteins, encoded by ORM1 and ORM2 (Otagiri et al. 1987). Once warfarin has entered the liver, S-warfarin is metabolised by cytochrome P450 2C9 (CYP2C9) (Rettie et al. 1992; Kaminsky and Zhang 1997). Patients with CYP2C9 variant alleles *2 and *3 alleles () require lower mean daily warfarin doses than extensive metabolisers homozygous for the *1 wild type allele do, and may have a greater risk of bleeding, especially during the induction of therapy (Sanderson et al. 2005). The enzymes CYP2C8, CYP2C18, CYP2C19 may also play a role in the metabolism of S-warfarin (Rettie et al. 1992; Kaminsky and Zhang 1997). R-warfarin is mainly metabolised by CYP1A2 and CYP3A4 (Rettie et al. 1992; Zhang et al. 1995; Kaminsky and Zhang 1997). In addition, CYP1A1, CYP2C8, CYP2C18, CYP2C19 and CYP3A5 may be involved in the metabolism of R-warfarin (Rettie et al. 1992; Zhang et al. 1995; Kaminsky and Zhang 1997; Huang et al. 2004). Cytochrome P450 enzymes are induced by the nuclear hormone receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR), which are encoded by NR1I2 and NR1I3 (Lehmann et al. 1998; Chen et al. 2004). Based on an inhibition assay, there is some evidence that transport of warfarin out of the liver and into the bile may be mediated by P-glycoprotein, which is encoded by ABCB1 (MDR1) (Sussman et al. 2002). P-glycoprotein can be induced by the nuclear hormone receptor PXR (Geick et al. 2001).
###end p 10
###begin p 11
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">2005</xref>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">2005</xref>
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">2005</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2006</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2006</xref>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">2006</xref>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2006</xref>
###xml 381 387 381 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C</italic>
We and others have shown that common variants in the VKORC1 and CYP2C9 genes together with a limited subset of environmental determinants account for around 50-60% of the variance in warfarin dose requirement (Sconce et al. 2005; Wadelius et al. 2005; Veenstra et al. 2005; Aquilante et al. 2006; Lee et al. 2006; Takahashi et al. 2006; Vecsler et al. 2006). Here, we fine map the VKORC1 and the CYP2C gene cluster loci on chromosomes 16 and 10, respectively, and assess common variation in 27 other genes in the warfarin interactive pathways for association with dose requirements. Finally, we evaluate the potential contribution of all positively associated genes to a warfarin dose model, which includes age, bodyweight, concomitant medication and indication for treatment.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
Subjects
###end title 13
###begin p 14
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">2004</xref>
###xml 333 336 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 959 963 957 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">2004</xref>
###xml 965 970 963 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">2005)</xref>
###xml 1090 1091 1088 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1221 1222 1219 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1255 1256 1253 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1279 1280 1277 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1312 1313 1310 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1494 1497 1492 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 1737 1738 1733 1734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1808 1809 1804 1805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1861 1862 1857 1858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 284 289 <span type="species:ncbi:9606">women</span>
###xml 762 770 <span type="species:ncbi:9606">patients</span>
###xml 868 876 <span type="species:ncbi:9606">patients</span>
###xml 972 980 <span type="species:ncbi:9606">Patients</span>
###xml 1052 1060 <span type="species:ncbi:9606">patients</span>
###xml 1153 1161 <span type="species:ncbi:9606">patients</span>
###xml 1535 1543 <span type="species:ncbi:9606">patients</span>
###xml 1820 1828 <span type="species:ncbi:9606">patients</span>
Two hundred and one Caucasian patients were recruited at Uppsala University Hospital in 2000; 194 patients of Swedish origin, four of other European descent and three from the Middle East (Wadelius et al. 2004). Their mean age was 66.7 years (range 28-88 years), and 1/3 of them were women. They had been treated with warfarin (Waran(R), Nycomed AB, Stockholm, Sweden) for a minimum of 2 months (range 2.4 months-26 years, median 2 years), and their prothrombin time international normalised ratio (PT INR) had been stabilised. At the six following visits, five weekly warfarin doses and five corresponding PT INR were registered. Individual warfarin dose requirement ranged from 4.5 to 77.25 mg/week. Information about age, gender, bodyweight (missing in seven patients), treatment indication and duration, other diseases and concurrent medication was taken from the patients' medical records, and the details have been presented previously (Wadelius et al. 2004, 2005). Patients were stratified into two groups depending on indication for treatment: patients with heart valve prosthesis (n = 49), where a higher target INR usually is recommended, and patients treated for other indications such as atrial fibrillation (n = 113), thromboembolic disease (n = 9), cardiomyopathy (n = 8) and transischemic attack (n = 5). Concurrent medications were registered, and drugs were classified as interacting if they had moderate or major interactions with warfarin according to the database MICROMEDEX(R) Healthcare Series () (May 2002). The patients had a total of 107 concurrent medications known to influence warfarin. They were divided into three groups: individuals with drugs that lower the effect of warfarin by inducing its metabolism (n = 4), those with medications that potentiate the effect of warfarin (n = 74) and patients without any known interactions (n = 123). The study was approved by the local Ethics Committee.
###end p 14
###begin title 15
Genotyping
###end title 15
###begin p 16
###xml 47 50 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
DNA was extracted from whole blood using QIAamp(R) DNA Blood Mini Kit (QIAGEN Ltd., Crawley, UK). Within the 29 candidate genes including 5 kb up- and downstream flanking regions, we selected available single nucleotide polymorphisms (SNPs), preferably with minor allele frequency (MAF) > 5% and spread out as evenly as possible every 2-5 kb. The first set of SNPs was selected from dbSNP () prior to the HapMap (), which was later used for gap filling in regions where the tested SNPs failed or were monomorphic in our population. In addition, we mined functional polymorphisms from the literature. In the process circa 900 SNPs were tested. SNP assays were designed with the SpectroDESIGNERtrade mark software.
###end p 16
###begin p 17
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX</italic>
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2005</xref>
###xml 417 420 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 770 774 736 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR63">2006</xref>
The GGCX microsatellite marker in intron 6 was analysed as described earlier (Chen et al. 2005). SNP typing was performed with the Homogeneous Mass Extend assay (Sequenom, Hamburg, Germany). Polymerase chain reaction (PCR) amplification was performed in 5-muL reactions using 3.5 ng DNA and 150 nM of each forward and reverse primer, 200 muM deoxynucleotide triphosphates (dNTPs), 1 x  PCR buffer, and 0.04 U Titanium(R) polymerase (BD BioSciences, Clontech, CA, USA). Cycling conditions were 94degreesC for 15 min, followed by 45 cycles of 94degreesC for 20 s, 56degreesC for 30 s and 72degreesC for 1 min, and then 72degreesC for 3 min. Primer extension, sample clean up and MALDI-TOF Mass Spectrometry analysis were performed as described elsewhere (Whittaker et al. 2006). Primer sequences are available on request.
###end p 17
###begin p 18
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Genotyping was carried out at a multiplex level of four SNPs per well and data quality was assessed by duplicate DNA (n = 4). SNPs with more than one discrepant call or showing self-priming in the negative control (water) were removed. Finally, we removed non-polymorphic SNPs, SNPs with call rate below 70%, and markers that departed from Hardy Weinberg equilibrium (P < 0.001).
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 393 394 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 394 397 394 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff</sub>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2001</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2001</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2004</xref>
###xml 529 533 529 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2002</xref>
###xml 778 782 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2003</xref>
###xml 828 829 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 829 830 829 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 865 869 865 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2001</xref>
###xml 956 957 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 957 958 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Univariate and multiple analyses of predictor's impact on the square root of warfarin dose were calculated using linear regression models as implemented by SAS and SPLUS software. To account for partial dependence among tests of SNPs in linkage disequilibrium (LD), we applied both the Bonferroni correction for multiple testing based on calculating the effective number of independent tests (Meff) and a Permutation procedure (Cheverud 2001; Li 2001; Nyholt 2004). LD was visualised using the HaploView software (Gabriel et al. 2002). The QTPHASE component of UNPHASED software was used to estimate haplotype frequencies, calculate means and variances of warfarin dose associated with each haplotype, and statistically test for differences among the haplotype means (Dudbridge 2003). Pairwise LD was quantified by the standard r2 measure (Pritchard and Przeworski 2001). The proportion of explained variance (coefficient of determination) was measured by R2.
###end p 20
###begin title 21
Results and discussion
###end title 21
###begin title 22
Association of warfarin dose with individual markers
###end title 22
###begin p 23
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 218 219 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 219 220 207 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 653 665 639 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1, GGCX</italic>
###xml 670 676 656 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 743 747 729 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">2005</xref>
###xml 885 948 871 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1, CYP2C9, CYP2C19, CYP2C18, PROC, EPHX1, CALU, GGCX, ORM1</italic>
###xml 953 957 939 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM2</italic>
###xml 1022 1023 1008 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1087 1091 1073 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 1092 1099 1078 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2, *E3</italic>
###xml 1105 1107 1091 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E4</italic>
###xml 1178 1179 1164 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1363 1364 1349 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 1364 1367 1350 1353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff</sub>
###xml 1421 1422 1407 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1450 1454 1436 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2001</xref>
###xml 1459 1463 1445 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2001</xref>
###xml 1472 1476 1458 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2004</xref>
###xml 1579 1580 1565 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 1580 1583 1566 1569 <sub xmlns:xlink="http://www.w3.org/1999/xlink">eff</sub>
###xml 1731 1732 1717 1718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1870 1871 1856 1857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1897 1898 1883 1884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1985 1991 1971 1977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 1993 1999 1979 1985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 2001 2008 1987 1994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 2013 2020 1999 2006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 2109 2113 2095 2099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 2118 2122 2104 2108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 2181 2182 2167 2168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 2189 2191 2175 2177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2</italic>
###xml 2201 2203 2187 2189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 2213 2215 2199 2201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F7</italic>
###xml 2225 2227 2211 2213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F9</italic>
###xml 2237 2240 2223 2226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F10</italic>
###xml 2253 2257 2239 2243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROZ</italic>
###xml 2267 2272 2253 2258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROS1</italic>
###xml 2284 2288 2270 2274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAS6</italic>
###xml 2300 2308 2286 2294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERPINC1</italic>
###xml 2320 2324 2306 2310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NQO1</italic>
###xml 2337 2343 2323 2329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1</italic>
###xml 2356 2362 2342 2348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A2</italic>
###xml 2373 2379 2359 2365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A4</italic>
###xml 2392 2398 2378 2384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 2408 2414 2394 2400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C8</italic>
###xml 2424 2429 2410 2415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR1I2</italic>
###xml 2441 2446 2427 2432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR1I3</italic>
###xml 2459 2464 2445 2450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1</italic>
###xml 2589 2596 2575 2582 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 2596 2704 2582 2690 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">Genes with significant association with warfarin dose, based on univariate regression of square root of dose</p>
###xml 2596 2704 2582 2690 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">Genes with significant association with warfarin dose, based on univariate regression of square root of dose</p></caption>
###xml 2704 2708 2690 2694 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gene</th>
###xml 2708 2711 2694 2697 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SNP</th>
###xml 2711 2714 2697 2700 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MAF</th>
###xml 2714 2715 2700 2701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2714 2715 2700 2701 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic></th>
###xml 2726 2727 2712 2713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 2727 2728 2713 2714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2715 2728 2701 2714 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Univariate <italic>R</italic><sup>2</sup></th>
###xml 2728 2729 2714 2715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2728 2735 2714 2721 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic>-Value</th>
###xml 2735 2736 2721 2722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2736 2737 2722 2723 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2735 2751 2721 2737 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>r</italic><sup>2</sup> with best SNP</th>
###xml 2704 2751 2690 2737 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Gene</th><th align="left">SNP</th><th align="left">MAF</th><th align="left"><italic>n</italic></th><th align="left">Univariate <italic>R</italic><sup>2</sup></th><th align="left"><italic>P</italic>-Value</th><th align="left"><italic>r</italic><sup>2</sup> with best SNP</th></tr>
###xml 2704 2751 2690 2737 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Gene</th><th align="left">SNP</th><th align="left">MAF</th><th align="left"><italic>n</italic></th><th align="left">Univariate <italic>R</italic><sup>2</sup></th><th align="left"><italic>P</italic>-Value</th><th align="left"><italic>r</italic><sup>2</sup> with best SNP</th></tr></thead>
###xml 2751 2757 2737 2743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 2751 2757 2737 2743 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="11"><italic>VKORC1</italic></td>
###xml 2757 2766 2743 2752 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9923231</td>
###xml 2766 2771 2752 2757 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.391</td>
###xml 2771 2774 2757 2760 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">181</td>
###xml 2774 2779 2760 2765 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.317</td>
###xml 2788 2791 2774 2777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;15</sup>
###xml 2779 2793 2765 2779 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.91&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td>
###xml 2793 2794 2779 2780 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 2751 2794 2737 2780 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="11"><italic>VKORC1</italic></td><td align="left">rs9923231</td><td char="." align="char">0.391</td><td align="left">181</td><td char="." align="char">0.317</td><td align="left">1.91&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td align="left">&#8211;</td></tr>
###xml 2794 2803 2780 2789 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2359612</td>
###xml 2803 2808 2789 2794 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.389</td>
###xml 2808 2811 2794 2797 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">200</td>
###xml 2811 2816 2797 2802 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.290</td>
###xml 2825 2828 2811 2814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;15</sup>
###xml 2816 2830 2802 2816 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.30&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td>
###xml 2830 2835 2816 2821 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.968</td>
###xml 2794 2835 2780 2821 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs2359612</td><td char="." align="char">0.389</td><td align="left">200</td><td char="." align="char">0.290</td><td align="left">2.30&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td char="." align="char">0.968</td></tr>
###xml 2835 2844 2821 2830 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9934438</td>
###xml 2844 2849 2830 2835 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.383</td>
###xml 2849 2852 2835 2838 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">169</td>
###xml 2852 2857 2838 2843 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.292</td>
###xml 2866 2869 2852 2855 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;13</sup>
###xml 2857 2871 2843 2857 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.59&#160;&#215;&#160;10<sup>&#8722;13</sup>**</td>
###xml 2871 2876 2857 2862 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.000</td>
###xml 2835 2876 2821 2862 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs9934438</td><td char="." align="char">0.383</td><td align="left">169</td><td char="." align="char">0.292</td><td align="left">3.59&#160;&#215;&#160;10<sup>&#8722;13</sup>**</td><td char="." align="char">1.000</td></tr>
###xml 2876 2882 2862 2868 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs7294</td>
###xml 2882 2887 2868 2873 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.384</td>
###xml 2887 2890 2873 2876 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">188</td>
###xml 2890 2895 2876 2881 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.208</td>
###xml 2904 2907 2890 2893 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;10</sup>
###xml 2895 2909 2881 2895 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.14&#160;&#215;&#160;10<sup>&#8722;10</sup>**</td>
###xml 2909 2914 2895 2900 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.385</td>
###xml 2876 2914 2862 2900 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs7294</td><td char="." align="char">0.384</td><td align="left">188</td><td char="." align="char">0.208</td><td align="left">4.14&#160;&#215;&#160;10<sup>&#8722;10</sup>**</td><td char="." align="char">0.385</td></tr>
###xml 2914 2923 2900 2909 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs4889490</td>
###xml 2923 2928 2909 2914 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.446</td>
###xml 2928 2931 2914 2917 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">199</td>
###xml 2931 2936 2917 2922 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.160</td>
###xml 2946 2948 2932 2934 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 2936 2950 2922 2936 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.821&#160;&#215;&#160;10<sup>&#8722;8</sup>**</td>
###xml 2950 2955 2936 2941 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.461</td>
###xml 2914 2955 2900 2941 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs4889490</td><td char="." align="char">0.446</td><td align="left">199</td><td char="." align="char">0.160</td><td align="left">3.821&#160;&#215;&#160;10<sup>&#8722;8</sup>**</td><td char="." align="char">0.461</td></tr>
###xml 2955 2964 2941 2950 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs4889537</td>
###xml 2964 2969 2950 2955 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.372</td>
###xml 2969 2972 2955 2958 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">199</td>
###xml 2972 2977 2958 2963 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.142</td>
###xml 2987 2989 2973 2975 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 2977 2991 2963 2977 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.158&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td>
###xml 2991 2996 2977 2982 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.209</td>
###xml 2955 2996 2941 2982 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs4889537</td><td char="." align="char">0.372</td><td align="left">199</td><td char="." align="char">0.142</td><td align="left">3.158&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.209</td></tr>
###xml 2996 3005 2982 2991 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs4889599</td>
###xml 3005 3010 2991 2996 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.366</td>
###xml 3010 3013 2996 2999 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">194</td>
###xml 3013 3018 2999 3004 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.124</td>
###xml 3028 3030 3014 3016 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 3018 3032 3004 3018 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.270&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td>
###xml 3032 3037 3018 3023 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.305</td>
###xml 2996 3037 2982 3023 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs4889599</td><td char="." align="char">0.366</td><td align="left">194</td><td char="." align="char">0.124</td><td align="left">3.270&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td char="." align="char">0.305</td></tr>
###xml 3037 3046 3023 3032 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs8046978</td>
###xml 3046 3051 3032 3037 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.214</td>
###xml 3051 3054 3037 3040 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">197</td>
###xml 3054 3059 3040 3045 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.047</td>
###xml 3059 3066 3045 3052 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00906</td>
###xml 3066 3071 3052 3057 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.173</td>
###xml 3037 3071 3023 3057 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs8046978</td><td char="." align="char">0.214</td><td align="left">197</td><td char="." align="char">0.047</td><td align="left">0.00906</td><td char="." align="char">0.173</td></tr>
###xml 3071 3081 3057 3067 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs11642603</td>
###xml 3081 3086 3067 3072 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.093</td>
###xml 3086 3089 3072 3075 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">192</td>
###xml 3089 3094 3075 3080 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.027</td>
###xml 3094 3101 3080 3087 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.02304</td>
###xml 3101 3106 3087 3092 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.070</td>
###xml 3071 3106 3057 3092 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs11642603</td><td char="." align="char">0.093</td><td align="left">192</td><td char="." align="char">0.027</td><td align="left">0.02304</td><td char="." align="char">0.070</td></tr>
###xml 3106 3116 3092 3102 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs11642466</td>
###xml 3116 3121 3102 3107 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.103</td>
###xml 3121 3124 3107 3110 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">195</td>
###xml 3124 3129 3110 3115 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.025</td>
###xml 3129 3136 3115 3122 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.02623</td>
###xml 3136 3141 3122 3127 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.080</td>
###xml 3106 3141 3092 3127 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs11642466</td><td char="." align="char">0.103</td><td align="left">195</td><td char="." align="char">0.025</td><td align="left">0.02623</td><td char="." align="char">0.080</td></tr>
###xml 3141 3150 3127 3136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs7194347</td>
###xml 3150 3155 3136 3141 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.343</td>
###xml 3155 3158 3141 3144 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">197</td>
###xml 3158 3163 3144 3149 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.032</td>
###xml 3163 3170 3149 3156 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.04069</td>
###xml 3170 3175 3156 3161 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.153</td>
###xml 3141 3175 3127 3161 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs7194347</td><td char="." align="char">0.343</td><td align="left">197</td><td char="." align="char">0.032</td><td align="left">0.04069</td><td char="." align="char">0.153</td></tr>
###xml 3175 3181 3161 3167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 3175 3181 3161 3167 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="7"><italic>CYP2C9</italic></td>
###xml 3181 3195 3167 3181 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1057910 (*3)</td>
###xml 3195 3200 3181 3186 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.058</td>
###xml 3200 3203 3186 3189 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">201</td>
###xml 3203 3208 3189 3194 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.141</td>
###xml 3218 3220 3204 3206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 3208 3222 3194 3208 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td>
###xml 3222 3223 3208 3209 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 3175 3223 3161 3209 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="7"><italic>CYP2C9</italic></td><td align="left">rs1057910 (*3)</td><td char="." align="char">0.058</td><td align="left">201</td><td char="." align="char">0.141</td><td align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td align="left">&#8211;</td></tr>
###xml 3223 3232 3209 3218 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9332108</td>
###xml 3232 3237 3218 3223 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.064</td>
###xml 3237 3240 3223 3226 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">201</td>
###xml 3240 3245 3226 3231 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.141</td>
###xml 3255 3257 3241 3243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 3245 3259 3231 3245 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td>
###xml 3259 3264 3245 3250 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.890</td>
###xml 3223 3264 3209 3250 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs9332108</td><td char="." align="char">0.064</td><td align="left">201</td><td char="." align="char">0.141</td><td align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.890</td></tr>
###xml 3264 3273 3250 3259 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9325473</td>
###xml 3273 3278 3259 3264 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.055</td>
###xml 3278 3281 3264 3267 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">189</td>
###xml 3281 3286 3267 3272 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.147</td>
###xml 3296 3298 3282 3284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 3286 3300 3272 3286 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.753&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td>
###xml 3300 3305 3286 3291 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.908</td>
###xml 3264 3305 3250 3291 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs9325473</td><td char="." align="char">0.055</td><td align="left">189</td><td char="." align="char">0.147</td><td align="left">3.753&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.908</td></tr>
###xml 3305 3314 3291 3300 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1057911</td>
###xml 3314 3319 3300 3305 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.067</td>
###xml 3319 3322 3305 3308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">191</td>
###xml 3322 3327 3308 3313 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.145</td>
###xml 3337 3339 3323 3325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 3327 3341 3313 3327 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.218&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td>
###xml 3341 3346 3327 3332 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.890</td>
###xml 3305 3346 3291 3332 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs1057911</td><td char="." align="char">0.067</td><td align="left">191</td><td char="." align="char">0.145</td><td align="left">4.218&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.890</td></tr>
###xml 3346 3355 3332 3341 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9332214</td>
###xml 3355 3360 3341 3346 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.059</td>
###xml 3360 3363 3346 3349 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">198</td>
###xml 3363 3368 3349 3354 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.139</td>
###xml 3378 3380 3364 3366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 3368 3382 3354 3368 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.654&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td>
###xml 3382 3387 3368 3373 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.878</td>
###xml 3346 3387 3332 3373 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs9332214</td><td char="." align="char">0.059</td><td align="left">198</td><td char="." align="char">0.139</td><td align="left">4.654&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.878</td></tr>
###xml 3387 3396 3373 3382 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs4917639</td>
###xml 3396 3401 3382 3387 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.173</td>
###xml 3401 3404 3387 3390 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">197</td>
###xml 3404 3409 3390 3395 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.118</td>
###xml 3419 3421 3405 3407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 3409 3423 3395 3409 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.944&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td>
###xml 3423 3428 3409 3414 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.276</td>
###xml 3387 3428 3373 3414 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs4917639</td><td char="." align="char">0.173</td><td align="left">197</td><td char="." align="char">0.118</td><td align="left">4.944&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td char="." align="char">0.276</td></tr>
###xml 3428 3437 3414 3423 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2860905</td>
###xml 3437 3442 3423 3428 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.214</td>
###xml 3442 3445 3428 3431 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">193</td>
###xml 3445 3450 3431 3436 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.072</td>
###xml 3450 3458 3436 3444 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00080*</td>
###xml 3458 3463 3444 3449 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.224</td>
###xml 3428 3463 3414 3449 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs2860905</td><td char="." align="char">0.214</td><td align="left">193</td><td char="." align="char">0.072</td><td align="left">0.00080*</td><td char="." align="char">0.224</td></tr>
###xml 3463 3470 3449 3456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 3463 3470 3449 3456 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>CYP2C19</italic></td>
###xml 3470 3479 3456 3465 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs3814637</td>
###xml 3479 3484 3465 3470 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.059</td>
###xml 3484 3487 3470 3473 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">195</td>
###xml 3487 3492 3473 3478 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.106</td>
###xml 3492 3501 3478 3487 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00002**</td>
###xml 3506 3507 3492 3493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 3501 3507 3487 3493 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.838<sup>a</sup></td>
###xml 3463 3507 3449 3493 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2"><italic>CYP2C19</italic></td><td align="left">rs3814637</td><td char="." align="char">0.059</td><td align="left">195</td><td char="." align="char">0.106</td><td align="left">0.00002**</td><td char="." align="char">0.838<sup>a</sup></td></tr>
###xml 3507 3522 3493 3508 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs17882687(*15)</td>
###xml 3522 3526 3508 3512 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.08</td>
###xml 3526 3529 3512 3515 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">183</td>
###xml 3529 3534 3515 3520 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.044</td>
###xml 3534 3542 3520 3528 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00417*</td>
###xml 3547 3548 3533 3534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 3542 3548 3528 3534 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.395<sup>a</sup></td>
###xml 3507 3548 3493 3534 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs17882687(*15)</td><td char="." align="char">0.08</td><td align="left">183</td><td char="." align="char">0.044</td><td align="left">0.00417*</td><td char="." align="char">0.395<sup>a</sup></td></tr>
###xml 3548 3555 3534 3541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 3548 3555 3534 3541 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C18</italic></td>
###xml 3555 3564 3541 3550 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs7896133</td>
###xml 3564 3569 3550 3555 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.056</td>
###xml 3569 3572 3555 3558 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">193</td>
###xml 3572 3577 3558 3563 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.074</td>
###xml 3577 3586 3563 3572 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00013**</td>
###xml 3591 3592 3577 3578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 3586 3592 3572 3578 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.869<sup>a</sup></td>
###xml 3548 3592 3534 3578 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C18</italic></td><td align="left">rs7896133</td><td char="." align="char">0.056</td><td align="left">193</td><td char="." align="char">0.074</td><td align="left">0.00013**</td><td char="." align="char">0.869<sup>a</sup></td></tr>
###xml 3592 3596 3578 3582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 3592 3596 3578 3582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="4"><italic>PROC</italic></td>
###xml 3596 3605 3582 3591 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2069919</td>
###xml 3605 3610 3591 3596 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.372</td>
###xml 3610 3613 3596 3599 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">182</td>
###xml 3613 3618 3599 3604 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.090</td>
###xml 3618 3626 3604 3612 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00022*</td>
###xml 3626 3627 3612 3613 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 3592 3627 3578 3613 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="4"><italic>PROC</italic></td><td align="left">rs2069919</td><td char="." align="char">0.372</td><td align="left">182</td><td char="." align="char">0.090</td><td align="left">0.00022*</td><td align="left">&#8211;</td></tr>
###xml 3627 3636 3613 3622 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1799809</td>
###xml 3636 3641 3622 3627 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.433</td>
###xml 3641 3644 3627 3630 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">188</td>
###xml 3644 3649 3630 3635 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.078</td>
###xml 3649 3657 3635 3643 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00055*</td>
###xml 3657 3662 3643 3648 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.777</td>
###xml 3627 3662 3613 3648 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs1799809</td><td char="." align="char">0.433</td><td align="left">188</td><td char="." align="char">0.078</td><td align="left">0.00055*</td><td char="." align="char">0.777</td></tr>
###xml 3662 3671 3648 3657 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2069901</td>
###xml 3671 3676 3657 3662 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.441</td>
###xml 3676 3679 3662 3665 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">177</td>
###xml 3679 3684 3665 3670 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.072</td>
###xml 3684 3692 3670 3678 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00147*</td>
###xml 3692 3697 3678 3683 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.785</td>
###xml 3662 3697 3648 3683 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs2069901</td><td char="." align="char">0.441</td><td align="left">177</td><td char="." align="char">0.072</td><td align="left">0.00147*</td><td char="." align="char">0.785</td></tr>
###xml 3697 3706 3683 3692 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2069910</td>
###xml 3706 3711 3692 3697 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.387</td>
###xml 3711 3714 3697 3700 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">178</td>
###xml 3714 3719 3700 3705 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.046</td>
###xml 3719 3726 3705 3712 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.01678</td>
###xml 3726 3731 3712 3717 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.414</td>
###xml 3697 3731 3683 3717 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs2069910</td><td char="." align="char">0.387</td><td align="left">178</td><td char="." align="char">0.046</td><td align="left">0.01678</td><td char="." align="char">0.414</td></tr>
###xml 3731 3735 3717 3721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 3731 3735 3717 3721 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>APOE</italic></td>
###xml 3752 3753 3738 3739 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 3735 3753 3721 3739 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs429358&#160;+&#160;rs7412<sup>b</sup></td>
###xml 3753 3758 3739 3744 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.251</td>
###xml 3758 3761 3744 3747 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">201</td>
###xml 3761 3766 3747 3752 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.051</td>
###xml 3766 3774 3752 3760 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00570*</td>
###xml 3774 3775 3760 3761 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 3731 3775 3717 3761 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>APOE</italic></td><td align="left">rs429358&#160;+&#160;rs7412<sup>b</sup></td><td char="." align="char">0.251</td><td align="left">201</td><td char="." align="char">0.051</td><td align="left">0.00570*</td><td align="left">&#8211;</td></tr>
###xml 3775 3780 3761 3766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EPHX1</italic>
###xml 3775 3780 3761 3766 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>EPHX1</italic></td>
###xml 3780 3789 3766 3775 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs4653436</td>
###xml 3789 3794 3775 3780 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.266</td>
###xml 3794 3797 3780 3783 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">196</td>
###xml 3797 3802 3783 3788 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.048</td>
###xml 3802 3809 3788 3795 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00848</td>
###xml 3809 3810 3795 3796 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 3775 3810 3761 3796 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>EPHX1</italic></td><td align="left">rs4653436</td><td char="." align="char">0.266</td><td align="left">196</td><td char="." align="char">0.048</td><td align="left">0.00848</td><td align="left">&#8211;</td></tr>
###xml 3810 3814 3796 3800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALU</italic>
###xml 3810 3814 3796 3800 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="4"><italic>CALU</italic></td>
###xml 3814 3821 3800 3807 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs11653</td>
###xml 3821 3826 3807 3812 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.366</td>
###xml 3826 3829 3812 3815 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">197</td>
###xml 3829 3834 3815 3820 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.047</td>
###xml 3834 3841 3820 3827 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.00944</td>
###xml 3841 3842 3827 3828 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 3810 3842 3796 3828 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="4"><italic>CALU</italic></td><td align="left">rs11653</td><td char="." align="char">0.366</td><td align="left">197</td><td char="." align="char">0.047</td><td align="left">0.00944</td><td align="left">&#8211;</td></tr>
###xml 3842 3851 3828 3837 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1006023</td>
###xml 3851 3856 3837 3842 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.331</td>
###xml 3856 3859 3842 3845 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">200</td>
###xml 3859 3864 3845 3850 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.033</td>
###xml 3864 3871 3850 3857 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.03789</td>
###xml 3871 3876 3857 3862 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.865</td>
###xml 3842 3876 3828 3862 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs1006023</td><td char="." align="char">0.331</td><td align="left">200</td><td char="." align="char">0.033</td><td align="left">0.03789</td><td char="." align="char">0.865</td></tr>
###xml 3876 3885 3862 3871 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2307040</td>
###xml 3885 3890 3871 3876 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.336</td>
###xml 3890 3893 3876 3879 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">200</td>
###xml 3893 3898 3879 3884 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.033</td>
###xml 3898 3905 3884 3891 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.03811</td>
###xml 3905 3910 3891 3896 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.867</td>
###xml 3876 3910 3862 3896 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs2307040</td><td char="." align="char">0.336</td><td align="left">200</td><td char="." align="char">0.033</td><td align="left">0.03811</td><td char="." align="char">0.867</td></tr>
###xml 3910 3918 3896 3904 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs339054</td>
###xml 3918 3923 3904 3909 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.461</td>
###xml 3923 3926 3909 3912 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">195</td>
###xml 3926 3931 3912 3917 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.032</td>
###xml 3931 3938 3917 3924 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.04487</td>
###xml 3938 3943 3924 3929 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.612</td>
###xml 3910 3943 3896 3929 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs339054</td><td char="." align="char">0.461</td><td align="left">195</td><td char="." align="char">0.032</td><td align="left">0.04487</td><td char="." align="char">0.612</td></tr>
###xml 3943 3947 3929 3933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX</italic>
###xml 3943 3947 3929 3933 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>GGCX</italic></td>
###xml 3947 3957 3933 3943 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs12714145</td>
###xml 3957 3962 3943 3948 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.408</td>
###xml 3962 3965 3948 3951 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">198</td>
###xml 3965 3970 3951 3956 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.034</td>
###xml 3970 3977 3956 3963 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.03320</td>
###xml 3977 3978 3963 3964 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 3943 3978 3929 3964 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>GGCX</italic></td><td align="left">rs12714145</td><td char="." align="char">0.408</td><td align="left">198</td><td char="." align="char">0.034</td><td align="left">0.03320</td><td align="left">&#8211;</td></tr>
###xml 3978 3984 3964 3970 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1-2</italic>
###xml 3978 3984 3964 3970 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>ORM1-2</italic></td>
###xml 3984 3993 3970 3979 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1687390</td>
###xml 3993 3998 3979 3984 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.062</td>
###xml 3998 4001 3984 3987 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">149</td>
###xml 4001 4006 3987 3992 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.026</td>
###xml 4006 4013 3992 3999 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.04964</td>
###xml 4013 4014 3999 4000 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 3978 4014 3964 4000 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>ORM1-2</italic></td><td align="left">rs1687390</td><td char="." align="char">0.062</td><td align="left">149</td><td char="." align="char">0.026</td><td align="left">0.04964</td><td align="left">&#8211;</td></tr>
###xml 2751 4014 2737 4000 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" rowspan="11"><italic>VKORC1</italic></td><td align="left">rs9923231</td><td char="." align="char">0.391</td><td align="left">181</td><td char="." align="char">0.317</td><td align="left">1.91&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td align="left">&#8211;</td></tr><tr><td align="left">rs2359612</td><td char="." align="char">0.389</td><td align="left">200</td><td char="." align="char">0.290</td><td align="left">2.30&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td char="." align="char">0.968</td></tr><tr><td align="left">rs9934438</td><td char="." align="char">0.383</td><td align="left">169</td><td char="." align="char">0.292</td><td align="left">3.59&#160;&#215;&#160;10<sup>&#8722;13</sup>**</td><td char="." align="char">1.000</td></tr><tr><td align="left">rs7294</td><td char="." align="char">0.384</td><td align="left">188</td><td char="." align="char">0.208</td><td align="left">4.14&#160;&#215;&#160;10<sup>&#8722;10</sup>**</td><td char="." align="char">0.385</td></tr><tr><td align="left">rs4889490</td><td char="." align="char">0.446</td><td align="left">199</td><td char="." align="char">0.160</td><td align="left">3.821&#160;&#215;&#160;10<sup>&#8722;8</sup>**</td><td char="." align="char">0.461</td></tr><tr><td align="left">rs4889537</td><td char="." align="char">0.372</td><td align="left">199</td><td char="." align="char">0.142</td><td align="left">3.158&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.209</td></tr><tr><td align="left">rs4889599</td><td char="." align="char">0.366</td><td align="left">194</td><td char="." align="char">0.124</td><td align="left">3.270&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td char="." align="char">0.305</td></tr><tr><td align="left">rs8046978</td><td char="." align="char">0.214</td><td align="left">197</td><td char="." align="char">0.047</td><td align="left">0.00906</td><td char="." align="char">0.173</td></tr><tr><td align="left">rs11642603</td><td char="." align="char">0.093</td><td align="left">192</td><td char="." align="char">0.027</td><td align="left">0.02304</td><td char="." align="char">0.070</td></tr><tr><td align="left">rs11642466</td><td char="." align="char">0.103</td><td align="left">195</td><td char="." align="char">0.025</td><td align="left">0.02623</td><td char="." align="char">0.080</td></tr><tr><td align="left">rs7194347</td><td char="." align="char">0.343</td><td align="left">197</td><td char="." align="char">0.032</td><td align="left">0.04069</td><td char="." align="char">0.153</td></tr><tr><td align="left" rowspan="7"><italic>CYP2C9</italic></td><td align="left">rs1057910 (*3)</td><td char="." align="char">0.058</td><td align="left">201</td><td char="." align="char">0.141</td><td align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td align="left">&#8211;</td></tr><tr><td align="left">rs9332108</td><td char="." align="char">0.064</td><td align="left">201</td><td char="." align="char">0.141</td><td align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.890</td></tr><tr><td align="left">rs9325473</td><td char="." align="char">0.055</td><td align="left">189</td><td char="." align="char">0.147</td><td align="left">3.753&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.908</td></tr><tr><td align="left">rs1057911</td><td char="." align="char">0.067</td><td align="left">191</td><td char="." align="char">0.145</td><td align="left">4.218&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.890</td></tr><tr><td align="left">rs9332214</td><td char="." align="char">0.059</td><td align="left">198</td><td char="." align="char">0.139</td><td align="left">4.654&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.878</td></tr><tr><td align="left">rs4917639</td><td char="." align="char">0.173</td><td align="left">197</td><td char="." align="char">0.118</td><td align="left">4.944&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td char="." align="char">0.276</td></tr><tr><td align="left">rs2860905</td><td char="." align="char">0.214</td><td align="left">193</td><td char="." align="char">0.072</td><td align="left">0.00080*</td><td char="." align="char">0.224</td></tr><tr><td align="left" rowspan="2"><italic>CYP2C19</italic></td><td align="left">rs3814637</td><td char="." align="char">0.059</td><td align="left">195</td><td char="." align="char">0.106</td><td align="left">0.00002**</td><td char="." align="char">0.838<sup>a</sup></td></tr><tr><td align="left">rs17882687(*15)</td><td char="." align="char">0.08</td><td align="left">183</td><td char="." align="char">0.044</td><td align="left">0.00417*</td><td char="." align="char">0.395<sup>a</sup></td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs7896133</td><td char="." align="char">0.056</td><td align="left">193</td><td char="." align="char">0.074</td><td align="left">0.00013**</td><td char="." align="char">0.869<sup>a</sup></td></tr><tr><td align="left" rowspan="4"><italic>PROC</italic></td><td align="left">rs2069919</td><td char="." align="char">0.372</td><td align="left">182</td><td char="." align="char">0.090</td><td align="left">0.00022*</td><td align="left">&#8211;</td></tr><tr><td align="left">rs1799809</td><td char="." align="char">0.433</td><td align="left">188</td><td char="." align="char">0.078</td><td align="left">0.00055*</td><td char="." align="char">0.777</td></tr><tr><td align="left">rs2069901</td><td char="." align="char">0.441</td><td align="left">177</td><td char="." align="char">0.072</td><td align="left">0.00147*</td><td char="." align="char">0.785</td></tr><tr><td align="left">rs2069910</td><td char="." align="char">0.387</td><td align="left">178</td><td char="." align="char">0.046</td><td align="left">0.01678</td><td char="." align="char">0.414</td></tr><tr><td align="left"><italic>APOE</italic></td><td align="left">rs429358&#160;+&#160;rs7412<sup>b</sup></td><td char="." align="char">0.251</td><td align="left">201</td><td char="." align="char">0.051</td><td align="left">0.00570*</td><td align="left">&#8211;</td></tr><tr><td align="left"><italic>EPHX1</italic></td><td align="left">rs4653436</td><td char="." align="char">0.266</td><td align="left">196</td><td char="." align="char">0.048</td><td align="left">0.00848</td><td align="left">&#8211;</td></tr><tr><td align="left" rowspan="4"><italic>CALU</italic></td><td align="left">rs11653</td><td char="." align="char">0.366</td><td align="left">197</td><td char="." align="char">0.047</td><td align="left">0.00944</td><td align="left">&#8211;</td></tr><tr><td align="left">rs1006023</td><td char="." align="char">0.331</td><td align="left">200</td><td char="." align="char">0.033</td><td align="left">0.03789</td><td char="." align="char">0.865</td></tr><tr><td align="left">rs2307040</td><td char="." align="char">0.336</td><td align="left">200</td><td char="." align="char">0.033</td><td align="left">0.03811</td><td char="." align="char">0.867</td></tr><tr><td align="left">rs339054</td><td char="." align="char">0.461</td><td align="left">195</td><td char="." align="char">0.032</td><td align="left">0.04487</td><td char="." align="char">0.612</td></tr><tr><td align="left"><italic>GGCX</italic></td><td align="left">rs12714145</td><td char="." align="char">0.408</td><td align="left">198</td><td char="." align="char">0.034</td><td align="left">0.03320</td><td align="left">&#8211;</td></tr><tr><td align="left"><italic>ORM1-2</italic></td><td align="left">rs1687390</td><td char="." align="char">0.062</td><td align="left">149</td><td char="." align="char">0.026</td><td align="left">0.04964</td><td align="left">&#8211;</td></tr></tbody>
###xml 2704 4014 2690 4000 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">SNP</th><th align="left">MAF</th><th align="left"><italic>n</italic></th><th align="left">Univariate <italic>R</italic><sup>2</sup></th><th align="left"><italic>P</italic>-Value</th><th align="left"><italic>r</italic><sup>2</sup> with best SNP</th></tr></thead><tbody><tr><td align="left" rowspan="11"><italic>VKORC1</italic></td><td align="left">rs9923231</td><td char="." align="char">0.391</td><td align="left">181</td><td char="." align="char">0.317</td><td align="left">1.91&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td align="left">&#8211;</td></tr><tr><td align="left">rs2359612</td><td char="." align="char">0.389</td><td align="left">200</td><td char="." align="char">0.290</td><td align="left">2.30&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td char="." align="char">0.968</td></tr><tr><td align="left">rs9934438</td><td char="." align="char">0.383</td><td align="left">169</td><td char="." align="char">0.292</td><td align="left">3.59&#160;&#215;&#160;10<sup>&#8722;13</sup>**</td><td char="." align="char">1.000</td></tr><tr><td align="left">rs7294</td><td char="." align="char">0.384</td><td align="left">188</td><td char="." align="char">0.208</td><td align="left">4.14&#160;&#215;&#160;10<sup>&#8722;10</sup>**</td><td char="." align="char">0.385</td></tr><tr><td align="left">rs4889490</td><td char="." align="char">0.446</td><td align="left">199</td><td char="." align="char">0.160</td><td align="left">3.821&#160;&#215;&#160;10<sup>&#8722;8</sup>**</td><td char="." align="char">0.461</td></tr><tr><td align="left">rs4889537</td><td char="." align="char">0.372</td><td align="left">199</td><td char="." align="char">0.142</td><td align="left">3.158&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.209</td></tr><tr><td align="left">rs4889599</td><td char="." align="char">0.366</td><td align="left">194</td><td char="." align="char">0.124</td><td align="left">3.270&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td char="." align="char">0.305</td></tr><tr><td align="left">rs8046978</td><td char="." align="char">0.214</td><td align="left">197</td><td char="." align="char">0.047</td><td align="left">0.00906</td><td char="." align="char">0.173</td></tr><tr><td align="left">rs11642603</td><td char="." align="char">0.093</td><td align="left">192</td><td char="." align="char">0.027</td><td align="left">0.02304</td><td char="." align="char">0.070</td></tr><tr><td align="left">rs11642466</td><td char="." align="char">0.103</td><td align="left">195</td><td char="." align="char">0.025</td><td align="left">0.02623</td><td char="." align="char">0.080</td></tr><tr><td align="left">rs7194347</td><td char="." align="char">0.343</td><td align="left">197</td><td char="." align="char">0.032</td><td align="left">0.04069</td><td char="." align="char">0.153</td></tr><tr><td align="left" rowspan="7"><italic>CYP2C9</italic></td><td align="left">rs1057910 (*3)</td><td char="." align="char">0.058</td><td align="left">201</td><td char="." align="char">0.141</td><td align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td align="left">&#8211;</td></tr><tr><td align="left">rs9332108</td><td char="." align="char">0.064</td><td align="left">201</td><td char="." align="char">0.141</td><td align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.890</td></tr><tr><td align="left">rs9325473</td><td char="." align="char">0.055</td><td align="left">189</td><td char="." align="char">0.147</td><td align="left">3.753&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.908</td></tr><tr><td align="left">rs1057911</td><td char="." align="char">0.067</td><td align="left">191</td><td char="." align="char">0.145</td><td align="left">4.218&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.890</td></tr><tr><td align="left">rs9332214</td><td char="." align="char">0.059</td><td align="left">198</td><td char="." align="char">0.139</td><td align="left">4.654&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.878</td></tr><tr><td align="left">rs4917639</td><td char="." align="char">0.173</td><td align="left">197</td><td char="." align="char">0.118</td><td align="left">4.944&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td char="." align="char">0.276</td></tr><tr><td align="left">rs2860905</td><td char="." align="char">0.214</td><td align="left">193</td><td char="." align="char">0.072</td><td align="left">0.00080*</td><td char="." align="char">0.224</td></tr><tr><td align="left" rowspan="2"><italic>CYP2C19</italic></td><td align="left">rs3814637</td><td char="." align="char">0.059</td><td align="left">195</td><td char="." align="char">0.106</td><td align="left">0.00002**</td><td char="." align="char">0.838<sup>a</sup></td></tr><tr><td align="left">rs17882687(*15)</td><td char="." align="char">0.08</td><td align="left">183</td><td char="." align="char">0.044</td><td align="left">0.00417*</td><td char="." align="char">0.395<sup>a</sup></td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs7896133</td><td char="." align="char">0.056</td><td align="left">193</td><td char="." align="char">0.074</td><td align="left">0.00013**</td><td char="." align="char">0.869<sup>a</sup></td></tr><tr><td align="left" rowspan="4"><italic>PROC</italic></td><td align="left">rs2069919</td><td char="." align="char">0.372</td><td align="left">182</td><td char="." align="char">0.090</td><td align="left">0.00022*</td><td align="left">&#8211;</td></tr><tr><td align="left">rs1799809</td><td char="." align="char">0.433</td><td align="left">188</td><td char="." align="char">0.078</td><td align="left">0.00055*</td><td char="." align="char">0.777</td></tr><tr><td align="left">rs2069901</td><td char="." align="char">0.441</td><td align="left">177</td><td char="." align="char">0.072</td><td align="left">0.00147*</td><td char="." align="char">0.785</td></tr><tr><td align="left">rs2069910</td><td char="." align="char">0.387</td><td align="left">178</td><td char="." align="char">0.046</td><td align="left">0.01678</td><td char="." align="char">0.414</td></tr><tr><td align="left"><italic>APOE</italic></td><td align="left">rs429358&#160;+&#160;rs7412<sup>b</sup></td><td char="." align="char">0.251</td><td align="left">201</td><td char="." align="char">0.051</td><td align="left">0.00570*</td><td align="left">&#8211;</td></tr><tr><td align="left"><italic>EPHX1</italic></td><td align="left">rs4653436</td><td char="." align="char">0.266</td><td align="left">196</td><td char="." align="char">0.048</td><td align="left">0.00848</td><td align="left">&#8211;</td></tr><tr><td align="left" rowspan="4"><italic>CALU</italic></td><td align="left">rs11653</td><td char="." align="char">0.366</td><td align="left">197</td><td char="." align="char">0.047</td><td align="left">0.00944</td><td align="left">&#8211;</td></tr><tr><td align="left">rs1006023</td><td char="." align="char">0.331</td><td align="left">200</td><td char="." align="char">0.033</td><td align="left">0.03789</td><td char="." align="char">0.865</td></tr><tr><td align="left">rs2307040</td><td char="." align="char">0.336</td><td align="left">200</td><td char="." align="char">0.033</td><td align="left">0.03811</td><td char="." align="char">0.867</td></tr><tr><td align="left">rs339054</td><td char="." align="char">0.461</td><td align="left">195</td><td char="." align="char">0.032</td><td align="left">0.04487</td><td char="." align="char">0.612</td></tr><tr><td align="left"><italic>GGCX</italic></td><td align="left">rs12714145</td><td char="." align="char">0.408</td><td align="left">198</td><td char="." align="char">0.034</td><td align="left">0.03320</td><td align="left">&#8211;</td></tr><tr><td align="left"><italic>ORM1-2</italic></td><td align="left">rs1687390</td><td char="." align="char">0.062</td><td align="left">149</td><td char="." align="char">0.026</td><td align="left">0.04964</td><td align="left">&#8211;</td></tr></tbody></table>
###xml 4050 4051 4036 4037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 4073 4074 4059 4060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 4074 4075 4060 4061 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 4109 4110 4095 4096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 4166 4167 4152 4153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 4014 4219 4000 4205 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25">The SNPs are listed with the lowest <italic>P</italic>-value first. The LD (<italic>r</italic><sup>2</sup>) between the SNP with the lowest <italic>P</italic>-value and others in the gene or gene cluster is shown. <italic>n</italic> is the number of successfully genotyped individuals</p>
###xml 4219 4220 4205 4206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4248 4256 4234 4242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*3</italic>
###xml 4219 4269 4205 4255 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26"><sup>a</sup>Linkage disequilibrium with <italic>CYP2C9*3</italic> (rs10579103)</p>
###xml 4269 4270 4255 4256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 4288 4292 4274 4278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 4354 4356 4340 4342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2</italic>
###xml 4359 4361 4345 4347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E4</italic>
###xml 4366 4368 4352 4354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E3</italic>
###xml 4269 4368 4255 4354 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27"><sup>b</sup>Note that the two <italic>APOE</italic> SNPs are not significant individually, only when assessed as <italic>E2</italic>&#160;+&#160;<italic>E4</italic> vs. <italic>E3</italic></p>
###xml 4368 4476 4354 4462 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">*The test is significant, based on correction for the effective number of tests in each gene or gene cluster</p>
###xml 4578 4579 4552 4553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 4591 4593 4565 4567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 4476 4594 4462 4568 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">**Corresponds to experiment-wise significance, based on &#8764;285 independent effective tests (<italic>P</italic>&#160;&lt;&#160;1.75&#160;&#215;&#160;10<sup>&#8722;4</sup>)</p>
###xml 4014 4594 4000 4568 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25">The SNPs are listed with the lowest <italic>P</italic>-value first. The LD (<italic>r</italic><sup>2</sup>) between the SNP with the lowest <italic>P</italic>-value and others in the gene or gene cluster is shown. <italic>n</italic> is the number of successfully genotyped individuals</p><p textid="26"><sup>a</sup>Linkage disequilibrium with <italic>CYP2C9*3</italic> (rs10579103)</p><p textid="27"><sup>b</sup>Note that the two <italic>APOE</italic> SNPs are not significant individually, only when assessed as <italic>E2</italic>&#160;+&#160;<italic>E4</italic> vs. <italic>E3</italic></p><p textid="28">*The test is significant, based on correction for the effective number of tests in each gene or gene cluster</p><p textid="29">**Corresponds to experiment-wise significance, based on &#8764;285 independent effective tests (<italic>P</italic>&#160;&lt;&#160;1.75&#160;&#215;&#160;10<sup>&#8722;4</sup>)</p></table-wrap-foot>
###xml 2589 4594 2575 4568 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="24">Genes with significant association with warfarin dose, based on univariate regression of square root of dose</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">SNP</th><th align="left">MAF</th><th align="left"><italic>n</italic></th><th align="left">Univariate <italic>R</italic><sup>2</sup></th><th align="left"><italic>P</italic>-Value</th><th align="left"><italic>r</italic><sup>2</sup> with best SNP</th></tr></thead><tbody><tr><td align="left" rowspan="11"><italic>VKORC1</italic></td><td align="left">rs9923231</td><td char="." align="char">0.391</td><td align="left">181</td><td char="." align="char">0.317</td><td align="left">1.91&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td align="left">&#8211;</td></tr><tr><td align="left">rs2359612</td><td char="." align="char">0.389</td><td align="left">200</td><td char="." align="char">0.290</td><td align="left">2.30&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td char="." align="char">0.968</td></tr><tr><td align="left">rs9934438</td><td char="." align="char">0.383</td><td align="left">169</td><td char="." align="char">0.292</td><td align="left">3.59&#160;&#215;&#160;10<sup>&#8722;13</sup>**</td><td char="." align="char">1.000</td></tr><tr><td align="left">rs7294</td><td char="." align="char">0.384</td><td align="left">188</td><td char="." align="char">0.208</td><td align="left">4.14&#160;&#215;&#160;10<sup>&#8722;10</sup>**</td><td char="." align="char">0.385</td></tr><tr><td align="left">rs4889490</td><td char="." align="char">0.446</td><td align="left">199</td><td char="." align="char">0.160</td><td align="left">3.821&#160;&#215;&#160;10<sup>&#8722;8</sup>**</td><td char="." align="char">0.461</td></tr><tr><td align="left">rs4889537</td><td char="." align="char">0.372</td><td align="left">199</td><td char="." align="char">0.142</td><td align="left">3.158&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.209</td></tr><tr><td align="left">rs4889599</td><td char="." align="char">0.366</td><td align="left">194</td><td char="." align="char">0.124</td><td align="left">3.270&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td char="." align="char">0.305</td></tr><tr><td align="left">rs8046978</td><td char="." align="char">0.214</td><td align="left">197</td><td char="." align="char">0.047</td><td align="left">0.00906</td><td char="." align="char">0.173</td></tr><tr><td align="left">rs11642603</td><td char="." align="char">0.093</td><td align="left">192</td><td char="." align="char">0.027</td><td align="left">0.02304</td><td char="." align="char">0.070</td></tr><tr><td align="left">rs11642466</td><td char="." align="char">0.103</td><td align="left">195</td><td char="." align="char">0.025</td><td align="left">0.02623</td><td char="." align="char">0.080</td></tr><tr><td align="left">rs7194347</td><td char="." align="char">0.343</td><td align="left">197</td><td char="." align="char">0.032</td><td align="left">0.04069</td><td char="." align="char">0.153</td></tr><tr><td align="left" rowspan="7"><italic>CYP2C9</italic></td><td align="left">rs1057910 (*3)</td><td char="." align="char">0.058</td><td align="left">201</td><td char="." align="char">0.141</td><td align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td align="left">&#8211;</td></tr><tr><td align="left">rs9332108</td><td char="." align="char">0.064</td><td align="left">201</td><td char="." align="char">0.141</td><td align="left">2.784&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.890</td></tr><tr><td align="left">rs9325473</td><td char="." align="char">0.055</td><td align="left">189</td><td char="." align="char">0.147</td><td align="left">3.753&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.908</td></tr><tr><td align="left">rs1057911</td><td char="." align="char">0.067</td><td align="left">191</td><td char="." align="char">0.145</td><td align="left">4.218&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.890</td></tr><tr><td align="left">rs9332214</td><td char="." align="char">0.059</td><td align="left">198</td><td char="." align="char">0.139</td><td align="left">4.654&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td char="." align="char">0.878</td></tr><tr><td align="left">rs4917639</td><td char="." align="char">0.173</td><td align="left">197</td><td char="." align="char">0.118</td><td align="left">4.944&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td char="." align="char">0.276</td></tr><tr><td align="left">rs2860905</td><td char="." align="char">0.214</td><td align="left">193</td><td char="." align="char">0.072</td><td align="left">0.00080*</td><td char="." align="char">0.224</td></tr><tr><td align="left" rowspan="2"><italic>CYP2C19</italic></td><td align="left">rs3814637</td><td char="." align="char">0.059</td><td align="left">195</td><td char="." align="char">0.106</td><td align="left">0.00002**</td><td char="." align="char">0.838<sup>a</sup></td></tr><tr><td align="left">rs17882687(*15)</td><td char="." align="char">0.08</td><td align="left">183</td><td char="." align="char">0.044</td><td align="left">0.00417*</td><td char="." align="char">0.395<sup>a</sup></td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs7896133</td><td char="." align="char">0.056</td><td align="left">193</td><td char="." align="char">0.074</td><td align="left">0.00013**</td><td char="." align="char">0.869<sup>a</sup></td></tr><tr><td align="left" rowspan="4"><italic>PROC</italic></td><td align="left">rs2069919</td><td char="." align="char">0.372</td><td align="left">182</td><td char="." align="char">0.090</td><td align="left">0.00022*</td><td align="left">&#8211;</td></tr><tr><td align="left">rs1799809</td><td char="." align="char">0.433</td><td align="left">188</td><td char="." align="char">0.078</td><td align="left">0.00055*</td><td char="." align="char">0.777</td></tr><tr><td align="left">rs2069901</td><td char="." align="char">0.441</td><td align="left">177</td><td char="." align="char">0.072</td><td align="left">0.00147*</td><td char="." align="char">0.785</td></tr><tr><td align="left">rs2069910</td><td char="." align="char">0.387</td><td align="left">178</td><td char="." align="char">0.046</td><td align="left">0.01678</td><td char="." align="char">0.414</td></tr><tr><td align="left"><italic>APOE</italic></td><td align="left">rs429358&#160;+&#160;rs7412<sup>b</sup></td><td char="." align="char">0.251</td><td align="left">201</td><td char="." align="char">0.051</td><td align="left">0.00570*</td><td align="left">&#8211;</td></tr><tr><td align="left"><italic>EPHX1</italic></td><td align="left">rs4653436</td><td char="." align="char">0.266</td><td align="left">196</td><td char="." align="char">0.048</td><td align="left">0.00848</td><td align="left">&#8211;</td></tr><tr><td align="left" rowspan="4"><italic>CALU</italic></td><td align="left">rs11653</td><td char="." align="char">0.366</td><td align="left">197</td><td char="." align="char">0.047</td><td align="left">0.00944</td><td align="left">&#8211;</td></tr><tr><td align="left">rs1006023</td><td char="." align="char">0.331</td><td align="left">200</td><td char="." align="char">0.033</td><td align="left">0.03789</td><td char="." align="char">0.865</td></tr><tr><td align="left">rs2307040</td><td char="." align="char">0.336</td><td align="left">200</td><td char="." align="char">0.033</td><td align="left">0.03811</td><td char="." align="char">0.867</td></tr><tr><td align="left">rs339054</td><td char="." align="char">0.461</td><td align="left">195</td><td char="." align="char">0.032</td><td align="left">0.04487</td><td char="." align="char">0.612</td></tr><tr><td align="left"><italic>GGCX</italic></td><td align="left">rs12714145</td><td char="." align="char">0.408</td><td align="left">198</td><td char="." align="char">0.034</td><td align="left">0.03320</td><td align="left">&#8211;</td></tr><tr><td align="left"><italic>ORM1-2</italic></td><td align="left">rs1687390</td><td char="." align="char">0.062</td><td align="left">149</td><td char="." align="char">0.026</td><td align="left">0.04964</td><td align="left">&#8211;</td></tr></tbody></table><table-wrap-foot><p textid="25">The SNPs are listed with the lowest <italic>P</italic>-value first. The LD (<italic>r</italic><sup>2</sup>) between the SNP with the lowest <italic>P</italic>-value and others in the gene or gene cluster is shown. <italic>n</italic> is the number of successfully genotyped individuals</p><p textid="26"><sup>a</sup>Linkage disequilibrium with <italic>CYP2C9*3</italic> (rs10579103)</p><p textid="27"><sup>b</sup>Note that the two <italic>APOE</italic> SNPs are not significant individually, only when assessed as <italic>E2</italic>&#160;+&#160;<italic>E4</italic> vs. <italic>E3</italic></p><p textid="28">*The test is significant, based on correction for the effective number of tests in each gene or gene cluster</p><p textid="29">**Corresponds to experiment-wise significance, based on &#8764;285 independent effective tests (<italic>P</italic>&#160;&lt;&#160;1.75&#160;&#215;&#160;10<sup>&#8722;4</sup>)</p></table-wrap-foot></table-wrap>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
We selected 29 candidate genes in the warfarin interactive pathways (Fig. 1 and Supplementary Table S1) and tested them for approximately800 SNPs that comprehensively captured common variation based on measures of LD (r2 >/= 0.8). In addition, we tested almost 100 functional polymorphisms including several published variants reported to be associated with warfarin dose, however, most of the tested functional SNPs were later excluded due to being monomorphic or having very low MAF. We identified 348 SNPs (Supplementary Table S2) that passed quality control and had a MAF of at least 4% in our sample of 201 warfarin patients. Note that results for VKORC1, GGCX and CYP2C9 are based on the reanalysis of SNPs presented by Wadelius et al. (2005) together with additional SNPs typed in this study. Univariate regression analysis showed that 32 polymorphisms in or flanking the genes VKORC1, CYP2C9, CYP2C19, CYP2C18, PROC, EPHX1, CALU, GGCX, ORM1 and ORM2 were nominally associated with warfarin dose requirement (Table 1). In addition, the two polymorphisms that discriminate between APOE*E2, *E3 and *E4 were significantly associated with dose when assessed together (Table 1). In determining correction for multiple testing, we compared the Permutation procedure with the Bonferroni correction based on the effective number of independent traits (Bonferroni Meff) and found that the two methods yielded very similar P-value cut-points (Cheverud 2001; Li 2001; Nyholt 2004). In this study, we present the number of effective tests within each gene obtained by the Bonferroni Meff method. The number of independent effective tests within each gene or gene cluster varied from 2 to 50, implying gene-wise corrected cut-points of P < 0.025 to < 0.001. Assuming that the genes are independent of each other, the sum of effective tests over all genes was 285. This makes P < 0.05/285, which equals P < 0.000175, the cut-off level for experiment-wise significance. Using this cut-point, VKORC1, CYP2C9, CYP2C18 and CYP2C19, were associated with dose after experiment-wise correction for multiple testing, while PROC and APOE were significant only after within-gene correction (Table 1). Ten F2 SNPs, 41 F5 SNPs, 11 F7 SNPs, 11 F9 SNPs, 15 F10 15 SNPs, 13 PROZ SNPs, 11 PROS1 SNPs, four GAS6 SNPs, nine SERPINC1 SNPs, nine NQO1 SNPs, three CYP1A1 SNPs, three CYP1A2 SNPs, two CYP3A4 SNPs, seven CYP3A5 SNPs, 12 CYP2C8 SNPs, 20 NR1I2 SNPs, nine NR1I3 SNPs and 38 ABCB1 SNPs passed the study criteria, but none of them were significantly associated with warfarin dose (Supplementary Table S2). Table 1Genes with significant association with warfarin dose, based on univariate regression of square root of doseGeneSNPMAFnUnivariate R2P-Valuer2 with best SNPVKORC1rs99232310.3911810.3171.91 x 10-15**-rs23596120.3892000.2902.30 x 10-15**0.968rs99344380.3831690.2923.59 x 10-13**1.000rs72940.3841880.2084.14 x 10-10**0.385rs48894900.4461990.1603.821 x 10-8**0.461rs48895370.3721990.1423.158 x 10-7**0.209rs48895990.3661940.1243.270 x 10-6**0.305rs80469780.2141970.0470.009060.173rs116426030.0931920.0270.023040.070rs116424660.1031950.0250.026230.080rs71943470.3431970.0320.040690.153CYP2C9rs1057910 (*3)0.0582010.1412.784 x 10-7**-rs93321080.0642010.1412.784 x 10-7**0.890rs93254730.0551890.1473.753 x 10-7**0.908rs10579110.0671910.1454.218 x 10-7**0.890rs93322140.0591980.1394.654 x 10-7**0.878rs49176390.1731970.1184.944 x 10-6**0.276rs28609050.2141930.0720.00080*0.224CYP2C19rs38146370.0591950.1060.00002**0.838ars17882687(*15)0.081830.0440.00417*0.395aCYP2C18rs78961330.0561930.0740.00013**0.869aPROCrs20699190.3721820.0900.00022*-rs17998090.4331880.0780.00055*0.777rs20699010.4411770.0720.00147*0.785rs20699100.3871780.0460.016780.414APOErs429358 + rs7412b0.2512010.0510.00570*-EPHX1rs46534360.2661960.0480.00848-CALUrs116530.3661970.0470.00944-rs10060230.3312000.0330.037890.865rs23070400.3362000.0330.038110.867rs3390540.4611950.0320.044870.612GGCXrs127141450.4081980.0340.03320-ORM1-2rs16873900.0621490.0260.04964-The SNPs are listed with the lowest P-value first. The LD (r2) between the SNP with the lowest P-value and others in the gene or gene cluster is shown. n is the number of successfully genotyped individualsaLinkage disequilibrium with CYP2C9*3 (rs10579103)bNote that the two APOE SNPs are not significant individually, only when assessed as E2 + E4 vs. E3*The test is significant, based on correction for the effective number of tests in each gene or gene cluster**Corresponds to experiment-wise significance, based on approximately285 independent effective tests (P < 1.75 x 10-4)
###end p 23
###begin p 24
Genes with significant association with warfarin dose, based on univariate regression of square root of dose
###end p 24
###begin p 25
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 152 153 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
The SNPs are listed with the lowest P-value first. The LD (r2) between the SNP with the lowest P-value and others in the gene or gene cluster is shown. n is the number of successfully genotyped individuals
###end p 25
###begin p 26
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 29 37 29 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*3</italic>
aLinkage disequilibrium with CYP2C9*3 (rs10579103)
###end p 26
###begin p 27
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 85 87 85 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2</italic>
###xml 90 92 90 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E4</italic>
###xml 97 99 97 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E3</italic>
bNote that the two APOE SNPs are not significant individually, only when assessed as E2 + E4 vs. E3
###end p 27
###begin p 28
*The test is significant, based on correction for the effective number of tests in each gene or gene cluster
###end p 28
###begin p 29
###xml 102 103 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 115 117 103 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
**Corresponds to experiment-wise significance, based on approximately285 independent effective tests (P < 1.75 x 10-4)
###end p 29
###begin title 30
Association of warfarin dose with haplotypes
###end title 30
###begin p 31
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 99 163 99 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1, CYP2C9, CYP2C8, CYP2C19, PROC, F7, GGCX, PROZ, F9, NR1I2</italic>
###xml 168 172 168 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1</italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM2</italic>
###xml 255 257 255 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F7</italic>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROZ</italic>
###xml 265 267 265 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F9</italic>
###xml 272 277 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR1I2</italic>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 348 349 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 403 409 403 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 411 417 411 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 419 426 419 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 431 438 431 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 541 545 541 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 584 591 584 591 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 639 640 639 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 591 669 591 669 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">Two or three marker haplotype giving the lowest <italic>P</italic>-value in each candidate gene</p>
###xml 591 669 591 669 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">Two or three marker haplotype giving the lowest <italic>P</italic>-value in each candidate gene</p></caption>
###xml 669 673 669 673 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gene</th>
###xml 673 682 673 682 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Haplotype</th>
###xml 682 683 682 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 682 689 682 689 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic>-value</th>
###xml 697 698 697 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 689 698 689 698 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Smaller?<sup>a</sup></th>
###xml 669 698 669 698 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Gene</th><th align="left">Haplotype</th><th align="left"><italic>P</italic>-value</th><th align="left">Smaller?<sup>a</sup></th></tr>
###xml 669 698 669 698 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Gene</th><th align="left">Haplotype</th><th align="left"><italic>P</italic>-value</th><th align="left">Smaller?<sup>a</sup></th></tr></thead>
###xml 698 704 698 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 698 704 698 704 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>VKORC1</italic></td>
###xml 704 723 704 723 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9934438-rs9923231</td>
###xml 732 735 732 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;15</sup>
###xml 723 737 723 737 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.76&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td>
###xml 737 739 737 739 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 698 739 698 739 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>VKORC1</italic></td><td align="left">rs9934438-rs9923231</td><td align="left">5.76&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td align="left">No</td></tr>
###xml 739 745 739 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 739 745 739 745 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 754 755 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 765 766 765 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 745 776 745 776 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9332214<sup>b</sup>-rs9332222<sup>c</sup>-rs2298037</td>
###xml 785 787 785 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 776 789 776 789 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.86&#160;&#215;&#160;10<sup>&#8722;9</sup>**</td>
###xml 789 792 789 792 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yes</bold>
###xml 789 792 789 792 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold>Yes</bold></td>
###xml 739 792 739 792 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332214<sup>b</sup>-rs9332222<sup>c</sup>-rs2298037</td><td align="left">4.86&#160;&#215;&#160;10<sup>&#8722;9</sup>**</td><td align="left"><bold>Yes</bold></td></tr>
###xml 792 799 792 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 792 799 792 799 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C18</italic></td>
###xml 818 819 818 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 799 830 799 830 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1926711-rs7919273<sup>b</sup>-rs10509675</td>
###xml 839 841 839 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 830 843 830 843 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.47&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td>
###xml 843 846 843 846 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yes</bold>
###xml 843 846 843 846 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold>Yes</bold></td>
###xml 792 846 792 846 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C18</italic></td><td align="left">rs1926711-rs7919273<sup>b</sup>-rs10509675</td><td align="left">3.47&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td align="left"><bold>Yes</bold></td></tr>
###xml 846 853 846 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 846 853 846 853 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C19</italic></td>
###xml 872 873 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 853 873 853 873 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2860840-rs3814637<sup>b</sup></td>
###xml 882 884 882 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 873 886 873 886 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.08&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td>
###xml 886 889 886 889 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yes</bold>
###xml 886 889 886 889 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold>Yes</bold></td>
###xml 846 889 846 889 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C19</italic></td><td align="left">rs2860840-rs3814637<sup>b</sup></td><td align="left">2.08&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td align="left"><bold>Yes</bold></td></tr>
###xml 889 893 889 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 889 893 889 893 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>PROC</italic></td>
###xml 893 921 893 921 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2069919-rs2069921-rs973760</td>
###xml 930 932 930 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 921 933 921 933 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.36&#160;&#215;&#160;10<sup>&#8722;3</sup>*</td>
###xml 933 935 933 935 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 889 935 889 935 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>PROC</italic></td><td align="left">rs2069919-rs2069921-rs973760</td><td align="left">1.36&#160;&#215;&#160;10<sup>&#8722;3</sup>*</td><td align="left">No</td></tr>
###xml 935 937 935 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F7</italic>
###xml 935 937 935 937 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>F7</italic></td>
###xml 937 956 937 956 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs3093229-rs3093233</td>
###xml 965 967 965 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;2</sup>
###xml 956 967 956 967 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.42&#160;&#215;&#160;10<sup>&#8722;2</sup></td>
###xml 967 970 967 970 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yes</bold>
###xml 967 970 967 970 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold>Yes</bold></td>
###xml 935 970 935 970 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>F7</italic></td><td align="left">rs3093229-rs3093233</td><td align="left">2.42&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr>
###xml 970 974 970 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX</italic>
###xml 970 974 970 974 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>GGCX</italic></td>
###xml 988 989 988 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 974 1008 974 1008 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Microsatellite<sup>d</sup>-rs762684-rs6738645</td>
###xml 1017 1019 1017 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;2</sup>
###xml 1008 1019 1008 1019 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.78&#160;&#215;&#160;10<sup>&#8722;2</sup></td>
###xml 1019 1022 1019 1022 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yes</bold>
###xml 1019 1022 1019 1022 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold>Yes</bold></td>
###xml 970 1022 970 1022 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>GGCX</italic></td><td align="left">Microsatellite<sup>d</sup>-rs762684-rs6738645</td><td align="left">1.78&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr>
###xml 1022 1026 1022 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROZ</italic>
###xml 1022 1026 1022 1026 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>PROZ</italic></td>
###xml 1026 1045 1026 1045 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2273971-rs3024711</td>
###xml 1054 1056 1054 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;2</sup>
###xml 1045 1056 1045 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.57&#160;&#215;&#160;10<sup>&#8722;2</sup></td>
###xml 1056 1059 1056 1059 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yes</bold>
###xml 1056 1059 1056 1059 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold>Yes</bold></td>
###xml 1022 1059 1022 1059 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>PROZ</italic></td><td align="left">rs2273971-rs3024711</td><td align="left">3.57&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr>
###xml 1059 1061 1059 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F9</italic>
###xml 1059 1061 1059 1061 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>F9</italic></td>
###xml 1061 1078 1061 1078 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs401597-rs392959</td>
###xml 1087 1089 1087 1089 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;2</sup>
###xml 1078 1089 1078 1089 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.83&#160;&#215;&#160;10<sup>&#8722;2</sup></td>
###xml 1089 1092 1089 1092 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yes</bold>
###xml 1089 1092 1089 1092 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold>Yes</bold></td>
###xml 1059 1092 1059 1092 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>F9</italic></td><td align="left">rs401597-rs392959</td><td align="left">3.83&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr>
###xml 1092 1097 1092 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR1I2</italic>
###xml 1092 1097 1092 1097 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>NR1I2</italic></td>
###xml 1097 1116 1097 1116 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2461818-rs7643645</td>
###xml 1125 1127 1125 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;2</sup>
###xml 1116 1127 1116 1127 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td>
###xml 1127 1130 1127 1130 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yes</bold>
###xml 1127 1130 1127 1130 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold>Yes</bold></td>
###xml 1092 1130 1092 1130 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>NR1I2</italic></td><td align="left">rs2461818-rs7643645</td><td align="left">3.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr>
###xml 1130 1136 1130 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1-2</italic>
###xml 1130 1136 1130 1136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>ORM1-2</italic></td>
###xml 1136 1155 1136 1155 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1687390-rs3762055</td>
###xml 1164 1166 1164 1166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;2</sup>
###xml 1155 1166 1155 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td>
###xml 1166 1168 1166 1168 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 1130 1168 1130 1168 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>ORM1-2</italic></td><td align="left">rs1687390-rs3762055</td><td align="left">4.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left">No</td></tr>
###xml 698 1168 698 1168 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left"><italic>VKORC1</italic></td><td align="left">rs9934438-rs9923231</td><td align="left">5.76&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td align="left">No</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332214<sup>b</sup>-rs9332222<sup>c</sup>-rs2298037</td><td align="left">4.86&#160;&#215;&#160;10<sup>&#8722;9</sup>**</td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs1926711-rs7919273<sup>b</sup>-rs10509675</td><td align="left">3.47&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>CYP2C19</italic></td><td align="left">rs2860840-rs3814637<sup>b</sup></td><td align="left">2.08&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>PROC</italic></td><td align="left">rs2069919-rs2069921-rs973760</td><td align="left">1.36&#160;&#215;&#160;10<sup>&#8722;3</sup>*</td><td align="left">No</td></tr><tr><td align="left"><italic>F7</italic></td><td align="left">rs3093229-rs3093233</td><td align="left">2.42&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>GGCX</italic></td><td align="left">Microsatellite<sup>d</sup>-rs762684-rs6738645</td><td align="left">1.78&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>PROZ</italic></td><td align="left">rs2273971-rs3024711</td><td align="left">3.57&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>F9</italic></td><td align="left">rs401597-rs392959</td><td align="left">3.83&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>NR1I2</italic></td><td align="left">rs2461818-rs7643645</td><td align="left">3.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>ORM1-2</italic></td><td align="left">rs1687390-rs3762055</td><td align="left">4.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left">No</td></tr></tbody>
###xml 669 1168 669 1168 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">Haplotype</th><th align="left"><italic>P</italic>-value</th><th align="left">Smaller?<sup>a</sup></th></tr></thead><tbody><tr><td align="left"><italic>VKORC1</italic></td><td align="left">rs9934438-rs9923231</td><td align="left">5.76&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td align="left">No</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332214<sup>b</sup>-rs9332222<sup>c</sup>-rs2298037</td><td align="left">4.86&#160;&#215;&#160;10<sup>&#8722;9</sup>**</td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs1926711-rs7919273<sup>b</sup>-rs10509675</td><td align="left">3.47&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>CYP2C19</italic></td><td align="left">rs2860840-rs3814637<sup>b</sup></td><td align="left">2.08&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>PROC</italic></td><td align="left">rs2069919-rs2069921-rs973760</td><td align="left">1.36&#160;&#215;&#160;10<sup>&#8722;3</sup>*</td><td align="left">No</td></tr><tr><td align="left"><italic>F7</italic></td><td align="left">rs3093229-rs3093233</td><td align="left">2.42&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>GGCX</italic></td><td align="left">Microsatellite<sup>d</sup>-rs762684-rs6738645</td><td align="left">1.78&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>PROZ</italic></td><td align="left">rs2273971-rs3024711</td><td align="left">3.57&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>F9</italic></td><td align="left">rs401597-rs392959</td><td align="left">3.83&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>NR1I2</italic></td><td align="left">rs2461818-rs7643645</td><td align="left">3.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>ORM1-2</italic></td><td align="left">rs1687390-rs3762055</td><td align="left">4.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left">No</td></tr></tbody></table>
###xml 1168 1169 1168 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1356 1357 1356 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1168 1382 1168 1382 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><italic>P</italic>-Values are arranged in ascending order and are based on QTPHASE haplotype test of association with square root of warfarin dose. Genes not shown did not produce a nominally significant (<italic>P</italic>&#160;&lt;&#160;0.05) haplotype result</p>
###xml 1382 1383 1382 1383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1416 1417 1416 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1444 1445 1444 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1382 1495 1382 1495 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34"><sup>a</sup>Yes indicates that the haplotype <italic>P</italic>-value is smaller than the <italic>P</italic>-value for the best single marker in the same gene</p>
###xml 1495 1496 1495 1496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1521 1529 1521 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*3</italic>
###xml 1495 1529 1495 1529 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><sup>b</sup>Strongly associated with <italic>CYP2C9*3</italic></p>
###xml 1529 1530 1529 1530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1555 1563 1555 1563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 1529 1563 1529 1563 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><sup>c</sup>Strongly associated with <italic>CYP2C9*2</italic></p>
###xml 1563 1564 1563 1564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 1564 1568 1564 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX</italic>
###xml 1610 1614 1610 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2005</xref>
###xml 1563 1615 1563 1615 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><sup>d</sup><italic>GGCX</italic> microsatellite described by Chen at al. (<xref ref-type="bibr" rid="CR8">2005</xref>)</p>
###xml 1717 1718 1717 1718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1755 1756 1755 1756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1615 1764 1615 1764 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38">*Gene-wise significance based on correcting for the effective number of tests in each gene. The other <italic>P</italic>-values are of nominal significance (<italic>P</italic>&#160;&lt;&#160;0.05)</p>
###xml 1796 1797 1796 1797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1809 1811 1809 1811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 1764 1812 1764 1812 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">**Experiment-wise significance (<italic>P</italic>&#160;&lt;&#160;1.75&#160;&#215;&#160;10<sup>&#8722;4</sup>)</p>
###xml 1168 1812 1168 1812 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33"><italic>P</italic>-Values are arranged in ascending order and are based on QTPHASE haplotype test of association with square root of warfarin dose. Genes not shown did not produce a nominally significant (<italic>P</italic>&#160;&lt;&#160;0.05) haplotype result</p><p textid="34"><sup>a</sup>Yes indicates that the haplotype <italic>P</italic>-value is smaller than the <italic>P</italic>-value for the best single marker in the same gene</p><p textid="35"><sup>b</sup>Strongly associated with <italic>CYP2C9*3</italic></p><p textid="36"><sup>c</sup>Strongly associated with <italic>CYP2C9*2</italic></p><p textid="37"><sup>d</sup><italic>GGCX</italic> microsatellite described by Chen at al. (<xref ref-type="bibr" rid="CR8">2005</xref>)</p><p textid="38">*Gene-wise significance based on correcting for the effective number of tests in each gene. The other <italic>P</italic>-values are of nominal significance (<italic>P</italic>&#160;&lt;&#160;0.05)</p><p textid="39">**Experiment-wise significance (<italic>P</italic>&#160;&lt;&#160;1.75&#160;&#215;&#160;10<sup>&#8722;4</sup>)</p></table-wrap-foot>
###xml 584 1812 584 1812 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="32">Two or three marker haplotype giving the lowest <italic>P</italic>-value in each candidate gene</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">Haplotype</th><th align="left"><italic>P</italic>-value</th><th align="left">Smaller?<sup>a</sup></th></tr></thead><tbody><tr><td align="left"><italic>VKORC1</italic></td><td align="left">rs9934438-rs9923231</td><td align="left">5.76&#160;&#215;&#160;10<sup>&#8722;15</sup>**</td><td align="left">No</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332214<sup>b</sup>-rs9332222<sup>c</sup>-rs2298037</td><td align="left">4.86&#160;&#215;&#160;10<sup>&#8722;9</sup>**</td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs1926711-rs7919273<sup>b</sup>-rs10509675</td><td align="left">3.47&#160;&#215;&#160;10<sup>&#8722;7</sup>**</td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>CYP2C19</italic></td><td align="left">rs2860840-rs3814637<sup>b</sup></td><td align="left">2.08&#160;&#215;&#160;10<sup>&#8722;6</sup>**</td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>PROC</italic></td><td align="left">rs2069919-rs2069921-rs973760</td><td align="left">1.36&#160;&#215;&#160;10<sup>&#8722;3</sup>*</td><td align="left">No</td></tr><tr><td align="left"><italic>F7</italic></td><td align="left">rs3093229-rs3093233</td><td align="left">2.42&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>GGCX</italic></td><td align="left">Microsatellite<sup>d</sup>-rs762684-rs6738645</td><td align="left">1.78&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>PROZ</italic></td><td align="left">rs2273971-rs3024711</td><td align="left">3.57&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>F9</italic></td><td align="left">rs401597-rs392959</td><td align="left">3.83&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>NR1I2</italic></td><td align="left">rs2461818-rs7643645</td><td align="left">3.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left"><bold>Yes</bold></td></tr><tr><td align="left"><italic>ORM1-2</italic></td><td align="left">rs1687390-rs3762055</td><td align="left">4.93&#160;&#215;&#160;10<sup>&#8722;2</sup></td><td align="left">No</td></tr></tbody></table><table-wrap-foot><p textid="33"><italic>P</italic>-Values are arranged in ascending order and are based on QTPHASE haplotype test of association with square root of warfarin dose. Genes not shown did not produce a nominally significant (<italic>P</italic>&#160;&lt;&#160;0.05) haplotype result</p><p textid="34"><sup>a</sup>Yes indicates that the haplotype <italic>P</italic>-value is smaller than the <italic>P</italic>-value for the best single marker in the same gene</p><p textid="35"><sup>b</sup>Strongly associated with <italic>CYP2C9*3</italic></p><p textid="36"><sup>c</sup>Strongly associated with <italic>CYP2C9*2</italic></p><p textid="37"><sup>d</sup><italic>GGCX</italic> microsatellite described by Chen at al. (<xref ref-type="bibr" rid="CR8">2005</xref>)</p><p textid="38">*Gene-wise significance based on correcting for the effective number of tests in each gene. The other <italic>P</italic>-values are of nominal significance (<italic>P</italic>&#160;&lt;&#160;0.05)</p><p textid="39">**Experiment-wise significance (<italic>P</italic>&#160;&lt;&#160;1.75&#160;&#215;&#160;10<sup>&#8722;4</sup>)</p></table-wrap-foot></table-wrap>
Haplotype analysis showed 12 genes to be nominally associated with warfarin dose (Table 2), namely VKORC1, CYP2C9, CYP2C8, CYP2C19, PROC, F7, GGCX, PROZ, F9, NR1I2 and ORM1-ORM2. Compared with the univariate single-marker analysis, four additional genes, F7, PROZ, F9 and NR1I2 were associated at P < 0.05. The haplotypes that exhibited the lowest P-values in each candidate gene are listed in Table 2. VKORC1, CYP2C9, CYP2C18 and CYP2C19 showed experiment-wise significance for haplotype analysis, as they did for single markers. Likewise, PROC was significant at a gene-wise level. Table 2Two or three marker haplotype giving the lowest P-value in each candidate geneGeneHaplotypeP-valueSmaller?aVKORC1rs9934438-rs99232315.76 x 10-15**NoCYP2C9rs9332214b-rs9332222c-rs22980374.86 x 10-9**YesCYP2C18rs1926711-rs7919273b-rs105096753.47 x 10-7**YesCYP2C19rs2860840-rs3814637b2.08 x 10-6**YesPROCrs2069919-rs2069921-rs9737601.36 x 10-3*NoF7rs3093229-rs30932332.42 x 10-2YesGGCXMicrosatellited-rs762684-rs67386451.78 x 10-2YesPROZrs2273971-rs30247113.57 x 10-2YesF9rs401597-rs3929593.83 x 10-2YesNR1I2rs2461818-rs76436453.93 x 10-2YesORM1-2rs1687390-rs37620554.93 x 10-2NoP-Values are arranged in ascending order and are based on QTPHASE haplotype test of association with square root of warfarin dose. Genes not shown did not produce a nominally significant (P < 0.05) haplotype resultaYes indicates that the haplotype P-value is smaller than the P-value for the best single marker in the same genebStrongly associated with CYP2C9*3cStrongly associated with CYP2C9*2dGGCX microsatellite described by Chen at al. (2005)*Gene-wise significance based on correcting for the effective number of tests in each gene. The other P-values are of nominal significance (P < 0.05)**Experiment-wise significance (P < 1.75 x 10-4)
###end p 31
###begin p 32
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Two or three marker haplotype giving the lowest P-value in each candidate gene
###end p 32
###begin p 33
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P-Values are arranged in ascending order and are based on QTPHASE haplotype test of association with square root of warfarin dose. Genes not shown did not produce a nominally significant (P < 0.05) haplotype result
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
aYes indicates that the haplotype P-value is smaller than the P-value for the best single marker in the same gene
###end p 34
###begin p 35
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*3</italic>
bStrongly associated with CYP2C9*3
###end p 35
###begin p 36
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
cStrongly associated with CYP2C9*2
###end p 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 1 5 1 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX</italic>
###xml 47 51 47 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2005</xref>
dGGCX microsatellite described by Chen at al. (2005)
###end p 37
###begin p 38
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
*Gene-wise significance based on correcting for the effective number of tests in each gene. The other P-values are of nominal significance (P < 0.05)
###end p 38
###begin p 39
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 45 47 45 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
**Experiment-wise significance (P < 1.75 x 10-4)
###end p 39
###begin title 40
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C</italic>
Fine mapping of the VKORC1 and CYP2C regions
###end title 40
###begin p 41
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 344 345 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 345 346 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 440 441 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 441 442 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 461 465 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">2005</xref>
###xml 516 522 492 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 559 565 535 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 579 580 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 739 745 715 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 745 747 721 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 752 754 728 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 964 970 928 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 1061 1062 1025 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1083 1089 1047 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 1120 1121 1084 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1181 1182 1145 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1184 1185 1148 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1649 1655 1613 1619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 1720 1724 1684 1688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">2005</xref>
###xml 1777 1781 1741 1745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">2005</xref>
###xml 1841 1845 1805 1809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2005</xref>
###xml 1848 1854 1812 1818 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1874 1880 1838 1844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 1888 1889 1852 1853 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1971 1977 1921 1927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 2102 2105 2052 2055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 2112 2113 2062 2063 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2129 2130 2079 2080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2130 2131 2080 2081 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2133 2148 2083 2098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pink, left axis</italic>
###xml 2154 2155 2104 2105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2163 2179 2113 2129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue, right axis</italic>
###xml 2227 2229 2177 2179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 2237 2242 2187 2192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 2262 2263 2212 2213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2353 2354 2303 2304 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2389 2390 2339 2340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2390 2391 2340 2341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2441 2460 2391 2410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red dotted triangle</italic>
###xml 1854 2535 1818 2485 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Fine mapping of the <italic>VKORC1</italic> locus. <bold>a</bold> Location of SNP markers (MAF&#160;&#8805;&#160;5%) in a &#8764;550&#160;kb region surrounding <italic>VKORC1</italic> which is coded on the reverse strand and is located at the right end of the LD block. Previously reported SNPs are shown in <italic>red</italic> (11). <bold>b</bold> The univariate <italic>r</italic><sup>2</sup> (<italic>pink, left axis</italic>) and <italic>P</italic>-value (<italic>blue, right axis</italic>) are shown for each SNP. The black line near 10<sup>&#8722;3</sup> on the <italic>right</italic> axis indicates the <italic>P</italic>-value that is necessary to achieve significance after within-gene Bonferroni correction. <bold>c</bold> HaploView analysis with pair-wise <italic>r</italic><sup>2</sup> illustrating the extent of LD in the region. The <italic>red dotted triangle</italic> indicates the LD block defined with data of the HapMap project (CEU panel)</p>
###xml 1854 2535 1818 2485 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Fine mapping of the <italic>VKORC1</italic> locus. <bold>a</bold> Location of SNP markers (MAF&#160;&#8805;&#160;5%) in a &#8764;550&#160;kb region surrounding <italic>VKORC1</italic> which is coded on the reverse strand and is located at the right end of the LD block. Previously reported SNPs are shown in <italic>red</italic> (11). <bold>b</bold> The univariate <italic>r</italic><sup>2</sup> (<italic>pink, left axis</italic>) and <italic>P</italic>-value (<italic>blue, right axis</italic>) are shown for each SNP. The black line near 10<sup>&#8722;3</sup> on the <italic>right</italic> axis indicates the <italic>P</italic>-value that is necessary to achieve significance after within-gene Bonferroni correction. <bold>c</bold> HaploView analysis with pair-wise <italic>r</italic><sup>2</sup> illustrating the extent of LD in the region. The <italic>red dotted triangle</italic> indicates the LD block defined with data of the HapMap project (CEU panel)</p></caption>
###xml 2535 2535 2485 2485 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="439_2006_260_Fig2_HTML" id="MO2"/>
###xml 1848 2535 1812 2485 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="42">Fine mapping of the <italic>VKORC1</italic> locus. <bold>a</bold> Location of SNP markers (MAF&#160;&#8805;&#160;5%) in a &#8764;550&#160;kb region surrounding <italic>VKORC1</italic> which is coded on the reverse strand and is located at the right end of the LD block. Previously reported SNPs are shown in <italic>red</italic> (11). <bold>b</bold> The univariate <italic>r</italic><sup>2</sup> (<italic>pink, left axis</italic>) and <italic>P</italic>-value (<italic>blue, right axis</italic>) are shown for each SNP. The black line near 10<sup>&#8722;3</sup> on the <italic>right</italic> axis indicates the <italic>P</italic>-value that is necessary to achieve significance after within-gene Bonferroni correction. <bold>c</bold> HaploView analysis with pair-wise <italic>r</italic><sup>2</sup> illustrating the extent of LD in the region. The <italic>red dotted triangle</italic> indicates the LD block defined with data of the HapMap project (CEU panel)</p></caption><graphic position="anchor" xlink:href="439_2006_260_Fig2_HTML" id="MO2"/></fig>
VKORC1 on chromosome 16 was the single gene most strongly associated with warfarin dose (Tables 1, 2). We previously described five SNPs in VKORC1 in an extended region of high LD spanning over 300 kb in the Swedish sample (Fig. 2). In this sample, three of the SNPs (rs2359612, rs9934438, rs9923231) were perfectly correlated with pairwise LD r2-values of approximately1.0 and accounted for approximately30% of the warfarin dose variance (R2) (Wadelius et al. 2005). An important goal of this study was to fine map VKORC1. Each of ten additional SNPs in the VKORC1 region (Fig. 2a) was tested to determine if it added significantly more dose variance to a multiple regression model that included one of the three linked SNPs (rs2359612), CYP2C9*2 and *3, and non-genetic predictors of warfarin dose (Supplementary Table S3). Our results demonstrated that: (a) each of the three linked SNPs predicted more dose variance (approximately30%) than any other genotyped VKORC1 SNP, and (b) none of the other ten flanking SNPs predicted additional dose variance (Fig. 2). In accordance, no VKORC1 haplotype yielded association P-values more significant than the three linked SNPs (Tables 1, 2). The molecular mechanism by which the three linked SNPs influence warfarin response has not been resolved. Due to the high LD between the three SNPs in our population, it is not possible to discern which of them that is responsible for the effect on warfarin. None of the studied SNPs are coding, and thus do not alter protein structure. Instead the effect may be mediated by altering the amount of drug target in the liver as postulated by studies showing that VKORC1 5' SNPs are correlated with liver levels of mRNA (Rieder et al. 2005) and with activity in a reporter assay (Yuan et al. 2005); however, a third study failed to show this (Bodin et al. 2005). Fig. 2Fine mapping of the VKORC1 locus. a Location of SNP markers (MAF >/= 5%) in a approximately550 kb region surrounding VKORC1 which is coded on the reverse strand and is located at the right end of the LD block. Previously reported SNPs are shown in red (11). b The univariate r2 (pink, left axis) and P-value (blue, right axis) are shown for each SNP. The black line near 10-3 on the right axis indicates the P-value that is necessary to achieve significance after within-gene Bonferroni correction. c HaploView analysis with pair-wise r2 illustrating the extent of LD in the region. The red dotted triangle indicates the LD block defined with data of the HapMap project (CEU panel)
###end p 41
###begin p 42
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 34 35 34 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 117 123 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 248 251 234 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 258 259 244 245 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 275 276 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 276 277 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 279 294 265 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pink, left axis</italic>
###xml 300 301 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 309 325 295 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue, right axis</italic>
###xml 373 375 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 383 388 369 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 408 409 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 499 500 485 486 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 535 536 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 536 537 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 587 606 573 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red dotted triangle</italic>
Fine mapping of the VKORC1 locus. a Location of SNP markers (MAF >/= 5%) in a approximately550 kb region surrounding VKORC1 which is coded on the reverse strand and is located at the right end of the LD block. Previously reported SNPs are shown in red (11). b The univariate r2 (pink, left axis) and P-value (blue, right axis) are shown for each SNP. The black line near 10-3 on the right axis indicates the P-value that is necessary to achieve significance after within-gene Bonferroni correction. c HaploView analysis with pair-wise r2 illustrating the extent of LD in the region. The red dotted triangle indicates the LD block defined with data of the HapMap project (CEU panel)
###end p 42
###begin p 43
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C</italic>
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 147 161 147 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9, CYP2C8</italic>
###xml 163 170 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 175 182 175 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C</italic>
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*3</italic>
###xml 445 449 445 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">1996</xref>
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 530 538 530 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 652 656 652 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">1994</xref>
###xml 730 735 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C</italic>
###xml 796 802 796 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 811 818 811 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 826 833 826 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 844 850 844 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C8</italic>
###xml 938 940 938 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 955 962 955 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 990 993 990 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*15</italic>
###xml 1018 1025 1018 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 1043 1044 1043 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1051 1061 1051 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19*2A</italic>
###xml 1184 1188 1184 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">1998</xref>
###xml 1204 1208 1204 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2002</xref>
###xml 1244 1249 1244 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C</italic>
###xml 1337 1345 1337 1345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 1350 1352 1350 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 1402 1403 1402 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 1428 1434 1428 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 1526 1534 1526 1534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 1543 1545 1543 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 1581 1586 1581 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C</italic>
###xml 1682 1688 1682 1688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 1767 1775 1767 1775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 1775 1777 1775 1777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">or</italic>
###xml 1777 1779 1777 1779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 1794 1800 1794 1800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 1834 1835 1834 1835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1854 1856 1854 1856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 1864 1865 1864 1865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1877 1879 1877 1879 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 1881 1884 1881 1884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">and</italic>
###xml 1889 1891 1889 1891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 1899 1900 1899 1900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1912 1914 1912 1914 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 1966 1967 1966 1967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1967 1968 1967 1968 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2026 2034 2026 2034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 2039 2041 2039 2041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 2073 2075 2073 2075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 2080 2082 2080 2082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 2141 2145 2141 2145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2006</xref>
###xml 2270 2272 2270 2272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 2277 2279 2277 2279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 2373 2378 2373 2378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2/*3</italic>
###xml 2508 2510 2508 2510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 2515 2517 2515 2517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 2632 2638 2632 2638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2/*3.</italic>
###xml 2638 2645 2638 2645 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 2658 2659 2658 2659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2645 2721 2645 2721 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Significant (<italic>P</italic>&#160;&lt;&#160;0.05) regression results for SNPs in the CYPC2 gene cluster</p>
###xml 2645 2721 2645 2721 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Significant (<italic>P</italic>&#160;&lt;&#160;0.05) regression results for SNPs in the CYPC2 gene cluster</p></caption>
###xml 2721 2725 2721 2725 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gene</th>
###xml 2725 2728 2725 2728 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SNP</th>
###xml 2728 2729 2728 2729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 2729 2730 2729 2730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2728 2745 2728 2745 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>R</italic><sup>2</sup> with *2 model </th>
###xml 2745 2746 2745 2746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2745 2752 2745 2752 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic>-Value</th>
###xml 2752 2753 2752 2753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 2753 2754 2753 2754 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2752 2769 2752 2769 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>R</italic><sup>2</sup> with *3 model </th>
###xml 2769 2770 2769 2770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2769 2776 2769 2776 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic>-Value</th>
###xml 2721 2776 2721 2776 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Gene</th><th align="left">SNP</th><th align="left"><italic>R</italic><sup>2</sup> with *2 model </th><th align="left"><italic>P</italic>-Value</th><th align="left"><italic>R</italic><sup>2</sup> with *3 model </th><th align="left"><italic>P</italic>-Value</th></tr>
###xml 2721 2776 2721 2776 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Gene</th><th align="left">SNP</th><th align="left"><italic>R</italic><sup>2</sup> with *2 model </th><th align="left"><italic>P</italic>-Value</th><th align="left"><italic>R</italic><sup>2</sup> with *3 model </th><th align="left"><italic>P</italic>-Value</th></tr></thead>
###xml 2776 2782 2776 2782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C8</italic>
###xml 2776 2782 2776 2782 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C8</italic></td>
###xml 2782 2792 2782 2792 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs11572080</td>
###xml 2792 2797 2792 2797 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.001</td>
###xml 2797 2802 2797 2802 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.502</td>
###xml 2802 2807 2802 2807 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.017</td>
###xml 2807 2812 2807 2812 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.005</td>
###xml 2776 2812 2776 2812 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C8</italic></td><td align="left">rs11572080</td><td char="." align="char">0.001</td><td align="left">0.502</td><td char="." align="char">0.017</td><td align="left">0.005</td></tr>
###xml 2812 2818 2812 2818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 2812 2818 2812 2818 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 2818 2827 2818 2827 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9332108</td>
###xml 2827 2832 2827 2832 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.109</td>
###xml 2841 2844 2841 2844 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;10</sup>
###xml 2832 2844 2832 2844 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td>
###xml 2844 2849 2844 2849 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000</td>
###xml 2849 2854 2849 2854 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.999</td>
###xml 2812 2854 2812 2854 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332108</td><td char="." align="char">0.109</td><td align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr>
###xml 2854 2860 2854 2860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 2854 2860 2854 2860 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 2871 2873 2871 2873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 2871 2873 2871 2873 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>*3</italic></bold>
###xml 2860 2874 2860 2874 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1057910 (<bold><italic>*3</italic></bold>)</td>
###xml 2874 2879 2874 2879 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.109</td>
###xml 2888 2891 2888 2891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;10</sup>
###xml 2879 2891 2879 2891 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td>
###xml 2891 2892 2891 2892 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 2892 2893 2892 2893 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 2854 2893 2854 2893 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1057910 (<bold><italic>*3</italic></bold>)</td><td char="." align="char">0.109</td><td align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td align="left">&#8211;</td><td align="left">&#8211;</td></tr>
###xml 2893 2899 2893 2899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 2893 2899 2893 2899 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 2899 2908 2899 2908 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1057911</td>
###xml 2908 2913 2908 2913 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.114</td>
###xml 2922 2925 2922 2925 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;10</sup>
###xml 2913 2925 2913 2925 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.97&#160;&#215;&#160;10<sup>&#8722;10</sup></td>
###xml 2925 2930 2925 2930 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000</td>
###xml 2930 2935 2930 2935 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.999</td>
###xml 2893 2935 2893 2935 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1057911</td><td char="." align="char">0.114</td><td align="left">2.97&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr>
###xml 2935 2941 2935 2941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 2935 2941 2935 2941 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 2941 2950 2941 2950 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9325473</td>
###xml 2950 2955 2950 2955 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.112</td>
###xml 2964 2967 2964 2967 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;10</sup>
###xml 2955 2967 2955 2967 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.45&#160;&#215;&#160;10<sup>&#8722;10</sup></td>
###xml 2967 2972 2967 2972 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000</td>
###xml 2972 2977 2972 2977 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.999</td>
###xml 2935 2977 2935 2977 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9325473</td><td char="." align="char">0.112</td><td align="left">5.45&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr>
###xml 2977 2983 2977 2983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 2977 2983 2977 2983 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 2983 2992 2983 2992 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs4917639</td>
###xml 2992 2997 2992 2997 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.100</td>
###xml 3006 3008 3006 3008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 2997 3008 2997 3008 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.33&#160;&#215;&#160;10<sup>&#8722;9</sup></td>
###xml 3008 3013 3008 3013 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.025</td>
###xml 3022 3024 3022 3024 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 3013 3024 3013 3024 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.56&#160;&#215;&#160;10<sup>&#8722;3</sup></td>
###xml 2977 3024 2977 3024 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4917639</td><td char="." align="char">0.100</td><td align="left">1.33&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.025</td><td align="left">3.56&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr>
###xml 3024 3030 3024 3030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 3024 3030 3024 3030 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 3030 3039 3030 3039 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9332214</td>
###xml 3039 3044 3039 3044 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.098</td>
###xml 3053 3055 3053 3055 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 3044 3055 3044 3055 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.50&#160;&#215;&#160;10<sup>&#8722;9</sup></td>
###xml 3055 3060 3055 3060 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000</td>
###xml 3060 3065 3060 3065 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.999</td>
###xml 3024 3065 3024 3065 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332214</td><td char="." align="char">0.098</td><td align="left">1.50&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr>
###xml 3065 3071 3065 3071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 3065 3071 3065 3071 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 3071 3080 3071 3080 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2860905</td>
###xml 3080 3085 3080 3085 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.048</td>
###xml 3094 3096 3094 3096 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 3085 3096 3085 3096 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.86&#160;&#215;&#160;10<sup>&#8722;4</sup></td>
###xml 3096 3101 3096 3101 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.009</td>
###xml 3101 3106 3101 3106 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.153</td>
###xml 3065 3106 3065 3106 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs2860905</td><td char="." align="char">0.048</td><td align="left">1.86&#160;&#215;&#160;10<sup>&#8722;4</sup></td><td char="." align="char">0.009</td><td align="left">0.153</td></tr>
###xml 3106 3112 3106 3112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 3106 3112 3106 3112 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 3112 3121 3112 3121 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs4917636</td>
###xml 3121 3126 3121 3126 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.004</td>
###xml 3126 3131 3126 3131 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.213</td>
###xml 3131 3136 3131 3136 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.026</td>
###xml 3145 3147 3145 3147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 3136 3147 3136 3147 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.63&#160;&#215;&#160;10<sup>&#8722;3</sup></td>
###xml 3106 3147 3106 3147 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4917636</td><td char="." align="char">0.004</td><td align="left">0.213</td><td char="." align="char">0.026</td><td align="left">3.63&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr>
###xml 3147 3153 3147 3153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 3147 3153 3147 3153 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 3153 3162 3153 3162 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs4607998</td>
###xml 3162 3167 3162 3167 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.004</td>
###xml 3167 3172 3167 3172 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.252</td>
###xml 3172 3177 3172 3177 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.026</td>
###xml 3186 3188 3186 3188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 3177 3188 3177 3188 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.85&#160;&#215;&#160;10<sup>&#8722;3</sup></td>
###xml 3147 3188 3147 3188 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4607998</td><td char="." align="char">0.004</td><td align="left">0.252</td><td char="." align="char">0.026</td><td align="left">2.85&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr>
###xml 3188 3194 3188 3194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 3188 3194 3188 3194 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 3205 3207 3205 3207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 3205 3207 3205 3207 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>*2</italic></bold>
###xml 3194 3208 3194 3208 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1799853 (<bold><italic>*2</italic></bold>)</td>
###xml 3208 3209 3208 3209 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 3209 3210 3209 3210 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 3210 3215 3210 3215 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.024</td>
###xml 3224 3226 3224 3226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 3215 3226 3215 3226 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.00&#160;&#215;&#160;10<sup>&#8722;3</sup></td>
###xml 3188 3226 3188 3226 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1799853 (<bold><italic>*2</italic></bold>)</td><td align="left">&#8211;</td><td align="left">&#8211;</td><td char="." align="char">0.024</td><td align="left">4.00&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr>
###xml 3226 3232 3226 3232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 3226 3232 3226 3232 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 3232 3241 3232 3241 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1934966</td>
###xml 3241 3246 3241 3246 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000</td>
###xml 3246 3251 3246 3251 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.999</td>
###xml 3251 3256 3251 3256 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.015</td>
###xml 3265 3267 3265 3267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 3256 3267 3256 3267 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8.72&#160;&#215;&#160;10<sup>&#8722;3</sup></td>
###xml 3226 3267 3226 3267 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1934966</td><td char="." align="char">0.000</td><td align="left">0.999</td><td char="." align="char">0.015</td><td align="left">8.72&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr>
###xml 3267 3273 3267 3273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 3267 3273 3267 3273 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 3273 3282 3273 3282 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9332222</td>
###xml 3282 3287 3282 3287 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000</td>
###xml 3287 3292 3287 3292 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.999</td>
###xml 3292 3297 3292 3297 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.025</td>
###xml 3306 3308 3306 3308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 3297 3308 3297 3308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.86&#160;&#215;&#160;10<sup>&#8722;3</sup></td>
###xml 3267 3308 3267 3308 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332222</td><td char="." align="char">0.000</td><td align="left">0.999</td><td char="." align="char">0.025</td><td align="left">3.86&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr>
###xml 3308 3315 3308 3315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 3308 3315 3308 3315 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C18</italic></td>
###xml 3315 3324 3315 3324 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs7896133</td>
###xml 3324 3329 3324 3329 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.063</td>
###xml 3338 3340 3338 3340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 3329 3340 3329 3340 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.17&#160;&#215;&#160;10<sup>&#8722;7</sup></td>
###xml 3340 3345 3340 3345 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000</td>
###xml 3345 3350 3345 3350 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.999</td>
###xml 3308 3350 3308 3350 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C18</italic></td><td align="left">rs7896133</td><td char="." align="char">0.063</td><td align="left">5.17&#160;&#215;&#160;10<sup>&#8722;7</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr>
###xml 3350 3357 3350 3357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C18</italic>
###xml 3350 3357 3350 3357 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C18</italic></td>
###xml 3357 3366 3357 3366 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2901783</td>
###xml 3366 3371 3366 3371 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.020</td>
###xml 3371 3376 3371 3376 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.029</td>
###xml 3376 3381 3376 3381 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.004</td>
###xml 3381 3386 3381 3386 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.471</td>
###xml 3350 3386 3350 3386 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C18</italic></td><td align="left">rs2901783</td><td char="." align="char">0.020</td><td align="left">0.029</td><td char="." align="char">0.004</td><td align="left">0.471</td></tr>
###xml 3386 3393 3386 3393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 3386 3393 3386 3393 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C19</italic></td>
###xml 3393 3402 3393 3402 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs3814637</td>
###xml 3402 3407 3402 3407 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.098</td>
###xml 3416 3418 3416 3418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 3407 3418 3407 3418 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.76&#160;&#215;&#160;10<sup>&#8722;9</sup></td>
###xml 3418 3423 3418 3423 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000</td>
###xml 3423 3428 3423 3428 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.896</td>
###xml 3386 3428 3386 3428 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C19</italic></td><td align="left">rs3814637</td><td char="." align="char">0.098</td><td align="left">3.76&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.000</td><td align="left">0.896</td></tr>
###xml 3428 3435 3428 3435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C19</italic>
###xml 3428 3435 3428 3435 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>CYP2C19</italic></bold>
###xml 3428 3435 3428 3435 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold><italic>CYP2C19</italic></bold></td>
###xml 3435 3445 3435 3445 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs17882687</td>
###xml 3445 3450 3445 3450 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.047</td>
###xml 3459 3461 3459 3461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 3450 3461 3450 3461 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.19&#160;&#215;&#160;10<sup>&#8722;5</sup></td>
###xml 3461 3466 3461 3466 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000</td>
###xml 3466 3471 3466 3471 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.828</td>
###xml 3428 3471 3428 3471 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><bold><italic>CYP2C19</italic></bold></td><td align="left">rs17882687</td><td char="." align="char">0.047</td><td align="left">5.19&#160;&#215;&#160;10<sup>&#8722;5</sup></td><td char="." align="char">0.000</td><td align="left">0.828</td></tr>
###xml 2776 3471 2776 3471 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left"><italic>CYP2C8</italic></td><td align="left">rs11572080</td><td char="." align="char">0.001</td><td align="left">0.502</td><td char="." align="char">0.017</td><td align="left">0.005</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332108</td><td char="." align="char">0.109</td><td align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1057910 (<bold><italic>*3</italic></bold>)</td><td char="." align="char">0.109</td><td align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td align="left">&#8211;</td><td align="left">&#8211;</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1057911</td><td char="." align="char">0.114</td><td align="left">2.97&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9325473</td><td char="." align="char">0.112</td><td align="left">5.45&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4917639</td><td char="." align="char">0.100</td><td align="left">1.33&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.025</td><td align="left">3.56&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332214</td><td char="." align="char">0.098</td><td align="left">1.50&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs2860905</td><td char="." align="char">0.048</td><td align="left">1.86&#160;&#215;&#160;10<sup>&#8722;4</sup></td><td char="." align="char">0.009</td><td align="left">0.153</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4917636</td><td char="." align="char">0.004</td><td align="left">0.213</td><td char="." align="char">0.026</td><td align="left">3.63&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4607998</td><td char="." align="char">0.004</td><td align="left">0.252</td><td char="." align="char">0.026</td><td align="left">2.85&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1799853 (<bold><italic>*2</italic></bold>)</td><td align="left">&#8211;</td><td align="left">&#8211;</td><td char="." align="char">0.024</td><td align="left">4.00&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1934966</td><td char="." align="char">0.000</td><td align="left">0.999</td><td char="." align="char">0.015</td><td align="left">8.72&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332222</td><td char="." align="char">0.000</td><td align="left">0.999</td><td char="." align="char">0.025</td><td align="left">3.86&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs7896133</td><td char="." align="char">0.063</td><td align="left">5.17&#160;&#215;&#160;10<sup>&#8722;7</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs2901783</td><td char="." align="char">0.020</td><td align="left">0.029</td><td char="." align="char">0.004</td><td align="left">0.471</td></tr><tr><td align="left"><italic>CYP2C19</italic></td><td align="left">rs3814637</td><td char="." align="char">0.098</td><td align="left">3.76&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.000</td><td align="left">0.896</td></tr><tr><td align="left"><bold><italic>CYP2C19</italic></bold></td><td align="left">rs17882687</td><td char="." align="char">0.047</td><td align="left">5.19&#160;&#215;&#160;10<sup>&#8722;5</sup></td><td char="." align="char">0.000</td><td align="left">0.828</td></tr></tbody>
###xml 2721 3471 2721 3471 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">SNP</th><th align="left"><italic>R</italic><sup>2</sup> with *2 model </th><th align="left"><italic>P</italic>-Value</th><th align="left"><italic>R</italic><sup>2</sup> with *3 model </th><th align="left"><italic>P</italic>-Value</th></tr></thead><tbody><tr><td align="left"><italic>CYP2C8</italic></td><td align="left">rs11572080</td><td char="." align="char">0.001</td><td align="left">0.502</td><td char="." align="char">0.017</td><td align="left">0.005</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332108</td><td char="." align="char">0.109</td><td align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1057910 (<bold><italic>*3</italic></bold>)</td><td char="." align="char">0.109</td><td align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td align="left">&#8211;</td><td align="left">&#8211;</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1057911</td><td char="." align="char">0.114</td><td align="left">2.97&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9325473</td><td char="." align="char">0.112</td><td align="left">5.45&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4917639</td><td char="." align="char">0.100</td><td align="left">1.33&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.025</td><td align="left">3.56&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332214</td><td char="." align="char">0.098</td><td align="left">1.50&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs2860905</td><td char="." align="char">0.048</td><td align="left">1.86&#160;&#215;&#160;10<sup>&#8722;4</sup></td><td char="." align="char">0.009</td><td align="left">0.153</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4917636</td><td char="." align="char">0.004</td><td align="left">0.213</td><td char="." align="char">0.026</td><td align="left">3.63&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4607998</td><td char="." align="char">0.004</td><td align="left">0.252</td><td char="." align="char">0.026</td><td align="left">2.85&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1799853 (<bold><italic>*2</italic></bold>)</td><td align="left">&#8211;</td><td align="left">&#8211;</td><td char="." align="char">0.024</td><td align="left">4.00&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1934966</td><td char="." align="char">0.000</td><td align="left">0.999</td><td char="." align="char">0.015</td><td align="left">8.72&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332222</td><td char="." align="char">0.000</td><td align="left">0.999</td><td char="." align="char">0.025</td><td align="left">3.86&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs7896133</td><td char="." align="char">0.063</td><td align="left">5.17&#160;&#215;&#160;10<sup>&#8722;7</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs2901783</td><td char="." align="char">0.020</td><td align="left">0.029</td><td char="." align="char">0.004</td><td align="left">0.471</td></tr><tr><td align="left"><italic>CYP2C19</italic></td><td align="left">rs3814637</td><td char="." align="char">0.098</td><td align="left">3.76&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.000</td><td align="left">0.896</td></tr><tr><td align="left"><bold><italic>CYP2C19</italic></bold></td><td align="left">rs17882687</td><td char="." align="char">0.047</td><td align="left">5.19&#160;&#215;&#160;10<sup>&#8722;5</sup></td><td char="." align="char">0.000</td><td align="left">0.828</td></tr></tbody></table>
###xml 3497 3498 3497 3498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 3498 3499 3498 3499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 3545 3546 3545 3546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3635 3641 3635 3641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 3714 3718 3714 3718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">2005</xref>
###xml 3721 3729 3721 3729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 3788 3796 3788 3796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*3</italic>
###xml 3848 3849 3848 3849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3864 3866 3864 3866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 3911 3913 3911 3913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 3933 3935 3933 3935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 4026 4028 4026 4028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 4032 4034 4032 4034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 3471 4089 3471 4089 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Additional dose variance (<italic>R</italic><sup>2</sup>) explained by each SNP and the corresponding <italic>P</italic>-value is shown for two multiple regression models of warfarin dose. Both models contain <italic>VKORC1</italic> SNP rs2359612 and non-genetic predictors identified by Wadelius et al. (<xref ref-type="bibr" rid="CR57">2005</xref>). <italic>CYP2C9*2</italic> is included in the first alternative regression model and <italic>CYP2C9*3</italic> is included in the second model. A non-significant <italic>P</italic>-value for the <italic>*2</italic> model but highly significant result for the <italic>*3</italic> model implies that <italic>*2</italic> fully accounts for the tested SNP&#8217;s contribution to dose variance (and vice versa). Thus, <italic>*2</italic> or <italic>*3</italic> fully account for each tested SNP apart from rs4917639</p>
###xml 4118 4119 4118 4119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 4089 4617 4089 4617 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">SNPs giving non-significant (<italic>P</italic>&#160;&gt;&#160;0.05) results in both models are: CYP2C8 (rs2275622, rs7898759, rs1557044, rs2275620, rs1341163, rs1891071, rs1058932, rs1058930, rs947173, rs17110453, rs3752988); CYP2C9 (rs9332197, rs2475376, rs1856908, rs1934964, rs2153628, rs10509679, rs2298037); CYP2C18 (rs10736086, rs10509675, rs12249418, rs7099637, rs7898763, rs7919273, rs1926706, rs2281891, rs1926711, rs7478002, rs2860837, rs2860840); CYP2C19 (rs4244284, rs12248560, rs3758580, rs4250786, rs17879456, rs17882419, rs4417205, rs1853205)</p>
###xml 3471 4617 3471 4617 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">Additional dose variance (<italic>R</italic><sup>2</sup>) explained by each SNP and the corresponding <italic>P</italic>-value is shown for two multiple regression models of warfarin dose. Both models contain <italic>VKORC1</italic> SNP rs2359612 and non-genetic predictors identified by Wadelius et al. (<xref ref-type="bibr" rid="CR57">2005</xref>). <italic>CYP2C9*2</italic> is included in the first alternative regression model and <italic>CYP2C9*3</italic> is included in the second model. A non-significant <italic>P</italic>-value for the <italic>*2</italic> model but highly significant result for the <italic>*3</italic> model implies that <italic>*2</italic> fully accounts for the tested SNP&#8217;s contribution to dose variance (and vice versa). Thus, <italic>*2</italic> or <italic>*3</italic> fully account for each tested SNP apart from rs4917639</p><p textid="46">SNPs giving non-significant (<italic>P</italic>&#160;&gt;&#160;0.05) results in both models are: CYP2C8 (rs2275622, rs7898759, rs1557044, rs2275620, rs1341163, rs1891071, rs1058932, rs1058930, rs947173, rs17110453, rs3752988); CYP2C9 (rs9332197, rs2475376, rs1856908, rs1934964, rs2153628, rs10509679, rs2298037); CYP2C18 (rs10736086, rs10509675, rs12249418, rs7099637, rs7898763, rs7919273, rs1926706, rs2281891, rs1926711, rs7478002, rs2860837, rs2860840); CYP2C19 (rs4244284, rs12248560, rs3758580, rs4250786, rs17879456, rs17882419, rs4417205, rs1853205)</p></table-wrap-foot>
###xml 2638 4617 2638 4617 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="44">Significant (<italic>P</italic>&#160;&lt;&#160;0.05) regression results for SNPs in the CYPC2 gene cluster</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">SNP</th><th align="left"><italic>R</italic><sup>2</sup> with *2 model </th><th align="left"><italic>P</italic>-Value</th><th align="left"><italic>R</italic><sup>2</sup> with *3 model </th><th align="left"><italic>P</italic>-Value</th></tr></thead><tbody><tr><td align="left"><italic>CYP2C8</italic></td><td align="left">rs11572080</td><td char="." align="char">0.001</td><td align="left">0.502</td><td char="." align="char">0.017</td><td align="left">0.005</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332108</td><td char="." align="char">0.109</td><td align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1057910 (<bold><italic>*3</italic></bold>)</td><td char="." align="char">0.109</td><td align="left">1.57&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td align="left">&#8211;</td><td align="left">&#8211;</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1057911</td><td char="." align="char">0.114</td><td align="left">2.97&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9325473</td><td char="." align="char">0.112</td><td align="left">5.45&#160;&#215;&#160;10<sup>&#8722;10</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4917639</td><td char="." align="char">0.100</td><td align="left">1.33&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.025</td><td align="left">3.56&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332214</td><td char="." align="char">0.098</td><td align="left">1.50&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs2860905</td><td char="." align="char">0.048</td><td align="left">1.86&#160;&#215;&#160;10<sup>&#8722;4</sup></td><td char="." align="char">0.009</td><td align="left">0.153</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4917636</td><td char="." align="char">0.004</td><td align="left">0.213</td><td char="." align="char">0.026</td><td align="left">3.63&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs4607998</td><td char="." align="char">0.004</td><td align="left">0.252</td><td char="." align="char">0.026</td><td align="left">2.85&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1799853 (<bold><italic>*2</italic></bold>)</td><td align="left">&#8211;</td><td align="left">&#8211;</td><td char="." align="char">0.024</td><td align="left">4.00&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1934966</td><td char="." align="char">0.000</td><td align="left">0.999</td><td char="." align="char">0.015</td><td align="left">8.72&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs9332222</td><td char="." align="char">0.000</td><td align="left">0.999</td><td char="." align="char">0.025</td><td align="left">3.86&#160;&#215;&#160;10<sup>&#8722;3</sup></td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs7896133</td><td char="." align="char">0.063</td><td align="left">5.17&#160;&#215;&#160;10<sup>&#8722;7</sup></td><td char="." align="char">0.000</td><td align="left">0.999</td></tr><tr><td align="left"><italic>CYP2C18</italic></td><td align="left">rs2901783</td><td char="." align="char">0.020</td><td align="left">0.029</td><td char="." align="char">0.004</td><td align="left">0.471</td></tr><tr><td align="left"><italic>CYP2C19</italic></td><td align="left">rs3814637</td><td char="." align="char">0.098</td><td align="left">3.76&#160;&#215;&#160;10<sup>&#8722;9</sup></td><td char="." align="char">0.000</td><td align="left">0.896</td></tr><tr><td align="left"><bold><italic>CYP2C19</italic></bold></td><td align="left">rs17882687</td><td char="." align="char">0.047</td><td align="left">5.19&#160;&#215;&#160;10<sup>&#8722;5</sup></td><td char="." align="char">0.000</td><td align="left">0.828</td></tr></tbody></table><table-wrap-foot><p textid="45">Additional dose variance (<italic>R</italic><sup>2</sup>) explained by each SNP and the corresponding <italic>P</italic>-value is shown for two multiple regression models of warfarin dose. Both models contain <italic>VKORC1</italic> SNP rs2359612 and non-genetic predictors identified by Wadelius et al. (<xref ref-type="bibr" rid="CR57">2005</xref>). <italic>CYP2C9*2</italic> is included in the first alternative regression model and <italic>CYP2C9*3</italic> is included in the second model. A non-significant <italic>P</italic>-value for the <italic>*2</italic> model but highly significant result for the <italic>*3</italic> model implies that <italic>*2</italic> fully accounts for the tested SNP&#8217;s contribution to dose variance (and vice versa). Thus, <italic>*2</italic> or <italic>*3</italic> fully account for each tested SNP apart from rs4917639</p><p textid="46">SNPs giving non-significant (<italic>P</italic>&#160;&gt;&#160;0.05) results in both models are: CYP2C8 (rs2275622, rs7898759, rs1557044, rs2275620, rs1341163, rs1891071, rs1058932, rs1058930, rs947173, rs17110453, rs3752988); CYP2C9 (rs9332197, rs2475376, rs1856908, rs1934964, rs2153628, rs10509679, rs2298037); CYP2C18 (rs10736086, rs10509675, rs12249418, rs7099637, rs7898763, rs7919273, rs1926706, rs2281891, rs1926711, rs7478002, rs2860837, rs2860840); CYP2C19 (rs4244284, rs12248560, rs3758580, rs4250786, rs17879456, rs17882419, rs4417205, rs1853205)</p></table-wrap-foot></table-wrap>
The CYP2C gene cluster on chromosome 10 was the second most strongly associated region after VKORC1 (Tables 1, 2). This region of high LD includes CYP2C9, CYP2C8, CYP2C18 and CYP2C19 (Supplementary Fig. S1). Several CYP2C SNPs were associated with warfarin dose, even after correction for multiple testing. The functional polymorphism in CYP2C9*3 (rs1057910, I359L), which severely impairs the capacity to hydroxylate S-warfarin (Haining et al. 1996), was the most strongly associated SNP in this region (Table 1). The functional CYP2C9*2 polymorphism (rs1799853, R144C) confers only a moderate reduction in the metabolism of S-warfarin (Rettie et al. 1994), and was not significant in univariate analysis. In fine mapping of the CYP2C region, we successfully genotyped 53 additional SNPs: 17 in CYP2C9, ten in CYP2C19, 14 in CYP2C18 and 12 in CYP2C8. In univariate analysis, significant association was observed for nine SNPs apart from *3 including the CYP2C19 5' upstream rs3814637, the *15 allele and the intronic CYP2C18 rs7896133 (Table 1). The CYP2C19*2A allele, which leads to an inactive CYP2C19 enzyme, was in agreement with earlier studies not associated (Takahashi et al. 1998; Scordo et al. 2002). To test whether any of the other CYP2C SNPs accounted for additional dose variance, apart from the 2.4 and 10.9% explained by CYP2C9*2 and *3, two multiple regression models were used (Table 3). Both models contained VKORC1 (rs2359612) and significant non-genetic predictors of warfarin dose, whereas one contained CYP2C9*2 but not *3 and vice versa. Each one of the 55 CYP2C SNPs was evaluated against the two multiple regression models. This showed that except for the CYP2C9 SNP rs4917639, all significant results were fully explained by LD with either CYP2C9*2or*3. In contrast, CYP2C9 SNP rs4917639 gave a significant P-value in both the *2 model (P < 1.33 x 10-9) and the *3 model (P < 3.56 x 10-3). The minor allele of rs4917639 was in perfect LD (r2 = 1) with a composite minor allele formed by aggregating CYP2C9*2 and *3 into a single allele, although *2 and *3 are rarely carried on the same haplotype (McGinnis et al. 2006). These data suggest that the rs4917639 mutation occurred first, and that rs1799853 and rs1057910, which are diagnostic for *2 and *3, arose independently on the same parent allele. The strong association between rs4917639 and *2/*3 could perhaps be due to positive selection, if rs4917639 lessened the deleterious effect of impaired CYP2C9 metabolism caused by *2 and *3. This and related possibilities merit further investigation given the unusual pattern of LD between rs4917639 and *2/*3.Table 3Significant (P < 0.05) regression results for SNPs in the CYPC2 gene clusterGeneSNPR2 with *2 model P-ValueR2 with *3 model P-ValueCYP2C8rs115720800.0010.5020.0170.005CYP2C9rs93321080.1091.57 x 10-100.0000.999CYP2C9rs1057910 (*3)0.1091.57 x 10-10--CYP2C9rs10579110.1142.97 x 10-100.0000.999CYP2C9rs93254730.1125.45 x 10-100.0000.999CYP2C9rs49176390.1001.33 x 10-90.0253.56 x 10-3CYP2C9rs93322140.0981.50 x 10-90.0000.999CYP2C9rs28609050.0481.86 x 10-40.0090.153CYP2C9rs49176360.0040.2130.0263.63 x 10-3CYP2C9rs46079980.0040.2520.0262.85 x 10-3CYP2C9rs1799853 (*2)--0.0244.00 x 10-3CYP2C9rs19349660.0000.9990.0158.72 x 10-3CYP2C9rs93322220.0000.9990.0253.86 x 10-3CYP2C18rs78961330.0635.17 x 10-70.0000.999CYP2C18rs29017830.0200.0290.0040.471CYP2C19rs38146370.0983.76 x 10-90.0000.896CYP2C19rs178826870.0475.19 x 10-50.0000.828Additional dose variance (R2) explained by each SNP and the corresponding P-value is shown for two multiple regression models of warfarin dose. Both models contain VKORC1 SNP rs2359612 and non-genetic predictors identified by Wadelius et al. (2005). CYP2C9*2 is included in the first alternative regression model and CYP2C9*3 is included in the second model. A non-significant P-value for the *2 model but highly significant result for the *3 model implies that *2 fully accounts for the tested SNP's contribution to dose variance (and vice versa). Thus, *2 or *3 fully account for each tested SNP apart from rs4917639SNPs giving non-significant (P > 0.05) results in both models are: CYP2C8 (rs2275622, rs7898759, rs1557044, rs2275620, rs1341163, rs1891071, rs1058932, rs1058930, rs947173, rs17110453, rs3752988); CYP2C9 (rs9332197, rs2475376, rs1856908, rs1934964, rs2153628, rs10509679, rs2298037); CYP2C18 (rs10736086, rs10509675, rs12249418, rs7099637, rs7898763, rs7919273, rs1926706, rs2281891, rs1926711, rs7478002, rs2860837, rs2860840); CYP2C19 (rs4244284, rs12248560, rs3758580, rs4250786, rs17879456, rs17882419, rs4417205, rs1853205)
###end p 43
###begin p 44
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Significant (P < 0.05) regression results for SNPs in the CYPC2 gene cluster
###end p 44
###begin p 45
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 243 247 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">2005</xref>
###xml 250 258 250 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 317 325 317 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*3</italic>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 393 395 393 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 440 442 440 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 462 464 462 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 555 557 555 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 561 563 561 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
Additional dose variance (R2) explained by each SNP and the corresponding P-value is shown for two multiple regression models of warfarin dose. Both models contain VKORC1 SNP rs2359612 and non-genetic predictors identified by Wadelius et al. (2005). CYP2C9*2 is included in the first alternative regression model and CYP2C9*3 is included in the second model. A non-significant P-value for the *2 model but highly significant result for the *3 model implies that *2 fully accounts for the tested SNP's contribution to dose variance (and vice versa). Thus, *2 or *3 fully account for each tested SNP apart from rs4917639
###end p 45
###begin p 46
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
SNPs giving non-significant (P > 0.05) results in both models are: CYP2C8 (rs2275622, rs7898759, rs1557044, rs2275620, rs1341163, rs1891071, rs1058932, rs1058930, rs947173, rs17110453, rs3752988); CYP2C9 (rs9332197, rs2475376, rs1856908, rs1934964, rs2153628, rs10509679, rs2298037); CYP2C18 (rs10736086, rs10509675, rs12249418, rs7099637, rs7898763, rs7919273, rs1926706, rs2281891, rs1926711, rs7478002, rs2860837, rs2860840); CYP2C19 (rs4244284, rs12248560, rs3758580, rs4250786, rs17879456, rs17882419, rs4417205, rs1853205)
###end p 46
###begin title 47
Other genes tentatively associated with warfarin dose
###end title 47
###begin p 48
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 414 418 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 530 531 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 750 754 750 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2005</xref>
###xml 1013 1017 1013 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">2003</xref>
###xml 1091 1095 1091 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 1220 1224 1220 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR68">1995</xref>
###xml 1239 1243 1239 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR67">1999</xref>
###xml 1328 1329 1328 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1432 1436 1432 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR68">1995</xref>
###xml 1451 1455 1451 1455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR67">1999</xref>
###xml 1492 1496 1492 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">2003</xref>
###xml 1769 1773 1769 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 1801 1805 1801 1805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2004</xref>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
###xml 961 969 <span type="species:ncbi:9606">patients</span>
Of the 13 PROC SNPs included in the analysis, four were significantly associated with dose: rs1799809 A > G and rs2069901 T > C in the 5' regulatory region of PROC, rs2069910 C > T in intron 2 and rs2069919 G > A in intron 3 (Table 1). The two promoter polymorphisms and the intron 3 polymorphism reached gene-wise significance and explained 7-9% of the variance in warfarin dose; P = 0.0002-0.0015. Haplotypes of PROC were also significantly associated with dose, but did not increase the statistical confidence since the lowest P-value was 0.00136 (Table 2). Unlike most other vitamin K-dependent factors, protein C acts as a natural anticoagulant by inactivating factors Va and VIIIa, but all its activities are not yet fully understood (Dahlback 2005). Intriguingly, it has previously been shown that protein C activity is negatively correlated with PT INR, not only in patients treated with oral anticoagulants, but also in healthy subjects and in medical patients without oral anticoagulants (Watala et al. 2003). Two other studies have found that homozygosity for the G allele of the PROC promoter polymorphism rs1799809 is associated with slightly reduced concentrations and activities of protein C (Spek et al. 1995; Aiach et al. 1999). In our study, carriers of rs1799809 G/G, had lower dose requirements than others (P = 0.00055). If rs1799809 G/G individuals have a reduced pre-treatment protein C activity (Spek et al. 1995; Aiach et al. 1999), which according to Watala et al. (2003) is associated with higher PT INR, then this might explain their low-warfarin dose requirements. However, this theory needs to be tested in a larger population. A Japanese group previously failed to find an association between warfarin dose and the rare synonymous coding PROC SNP rs5935 (Shikata et al. 2004), which was not polymorphic in our sample.
###end p 48
###begin p 49
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 58 66 58 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*E2, *E3</italic>
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*E4</italic>
###xml 130 133 130 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*E4</italic>
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*E2</italic>
###xml 198 201 198 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*E3</italic>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 386 393 386 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE*E4</italic>
###xml 460 461 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 486 491 486 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2005b</xref>
###xml 612 619 612 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE*E4</italic>
###xml 658 662 658 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">2005</xref>
###xml 705 712 705 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE*E4</italic>
###xml 787 790 787 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*E4</italic>
###xml 897 901 897 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 939 944 939 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2005a</xref>
###xml 1033 1037 1033 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 91 99 <span type="species:ncbi:9606">Patients</span>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
We analysed the two APOE SNPs that define the widely used *E2, *E3 and *E4 allelic system. Patients who carried the common allele *E4 or the rarer *E2 required higher warfarin doses than those with *E3; P = 0.0057. This result was significant after within-gene correction for multiple testing (Table 1). We previously reported that CYP2C9 extensive metabolisers who were homozygous for APOE*E4 required higher warfarin doses than other extensive metabolisers; P = 0.0008 (Kohnke et al. 2005b). This is supported by a Dutch study that found slightly higher maintenance doses of the anticoagulant phenprocoumon in APOE*E4 homozygous individuals (Visser et al. 2005). Surprisingly, the same study found that APOE*E4 carriers required lower maintenance doses of acenocoumarol. No homozygous *E4 individuals were found among Italian patients, and the association between warfarin dose requirements and APOE genotype was not seen (Kohnke et al. 2005a). These discrepant results indicate that the association between anticoagulant dose and APOE, if any, is weak. In addition, they point out that a future warfarin dose prediction model may not be applicable to phenprocoumon and acenocoumaron.
###end p 49
###begin p 50
###xml 113 151 113 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX, F7, PROZ, F9, EPHX1, CALU, NR1I2</italic>
###xml 153 157 153 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM2</italic>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX</italic>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2004</xref>
###xml 338 342 338 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2005</xref>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2005</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 637 639 637 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2</italic>
###xml 711 715 711 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2004</xref>
###xml 732 736 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2004</xref>
###xml 771 772 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 783 785 783 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F7</italic>
###xml 787 790 787 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F10</italic>
###xml 795 799 795 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROZ</italic>
###xml 839 841 839 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F7</italic>
###xml 938 942 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2004</xref>
###xml 959 963 959 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2004</xref>
###xml 982 986 982 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2006</xref>
###xml 1026 1028 1026 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F7</italic>
###xml 1080 1084 1080 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROZ</italic>
###xml 1166 1167 1166 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1200 1202 1200 1202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F7</italic>
###xml 1308 1312 1308 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">1994</xref>
###xml 1362 1365 1362 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F10</italic>
###xml 1413 1417 1413 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2004</xref>
###xml 1440 1442 1440 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F9</italic>
###xml 1556 1560 1556 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">2002</xref>
###xml 1585 1589 1585 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2004</xref>
###xml 1714 1715 1714 1715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1850 1855 1850 1855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EPHX1</italic>
###xml 1957 1961 1957 1961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2005</xref>
###xml 2082 2083 2082 2083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 2102 2106 2102 2106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALU</italic>
###xml 2173 2179 2173 2179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 2184 2190 2184 2190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 2226 2230 2226 2230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2006</xref>
###xml 2310 2314 2310 2314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALU</italic>
###xml 2429 2430 2429 2430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2445 2446 2445 2446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 2527 2532 2527 2532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR1I2</italic>
###xml 2587 2588 2587 2588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 2645 2649 2645 2649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1</italic>
###xml 2654 2658 2654 2658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM2</italic>
###xml 2734 2735 2734 2735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 2737 2738 2737 2738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 2938 2940 2938 2940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 3022 3023 3022 3023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1535 1543 <span type="species:ncbi:9606">patients</span>
###xml 2201 2209 <span type="species:ncbi:9606">patients</span>
Nine other genes were nominally associated with warfarin dose, but did not pass correction for multiple testing: GGCX, F7, PROZ, F9, EPHX1, CALU, NR1I2, ORM1 and ORM2 (Tables 1, 2). It has been shown that warfarin dose tends to increase with the number of repeats of a microsatellite in intron 6 of GGCX (Shikata et al. 2004; Chen et al. 2005). A haplotype including the microsatellite was more significant than the intron 2 SNP rs12714145 reported by Chen et al. (2005), however, both failed to reach gene-wise significance (Tables 1, 2). The SNP rs5896 causing a threonine to methionine change at position 165 in the prothrombin gene (F2), which was reported to confer warfarin sensitivity (D'Ambrosio et al. 2004; Shikata et al. 2004), did not replicate in our study; P = 0.2923. F7, F10 and PROZ are positioned in close proximity, and F7 promoter polymorphisms are claimed to have an effect on warfarin sensitivity (D'Ambrosio et al. 2004; Shikata et al. 2004; Aquilante et al. 2006). A haplotype located 2 kb upstream of F7 was tentatively associated with dose, and so was a PROZ haplotype comprising SNPs 5' upstream of the gene and in the first intron (Table 2). On the other hand, the coding F7 SNP rs6046 (R413Q, formerly R353Q) that may lead to decreased plasma levels of factor VII (Arbini et al. 1994), and the synonymous SNP rs5960 in the exon 7 of F10 did not affect warfarin dosing (Shikata et al. 2004). The rare variant in F9 (A-10V/T) that causes a disproportional reduction in factor IX activity in warfarin-treated patients (Kristensen 2002; van der Heijden et al. 2004) was not found in our study population, although a haplotype covering this region showed nominal association to dose (Table 2). A recent study has shown an association between high doses of warfarin in CYP2C9 extensive metabolisers carrying the non-synonymous EPHX1 SNP rs1051740 which results in a tyrosine to histidine substitution at residue 113 (Loebstein et al. 2005). We failed to replicate this finding, although rs4653436 located 5' upstream was nominally associated with dose (Table 1). A coding SNP in CALU (R4Q), that is suspected to increase warfarin dose requirement in CYP2C9 and VKORC1 wild type patients (Vecsler et al. 2006), was not significantly associated with dose in our study. However, the 3' UTR CALU SNP rs11653, the non-synonymous rs2307040 and the two intronic rs339054 and rs1006023 gave borderline significant P-values (Table 1). The nominal association between warfarin dose requirements and a haplotype of NR1I2 has to our knowledge not previously been shown (Table 2). Warfarin's association with rs3762055 located between ORM1 and ORM2, and with a haplotype covering this region are also novel findings (Tables 1, 2). The weaker associations observed for these tentatively associated genes require testing and validation in an independent and larger data set. Finally, it is worth mentioning that the prothrombotic F5 Leiden variant (rs6025) had no effect on warfarin dose requirement in our study (P = 0.4925).
###end p 50
###begin title 51
Multiple modelling
###end title 51
###begin p 52
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 134 140 134 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 390 453 390 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1, CYP2C9, CYP2C19, CYP2C18, PROC, APOE, EPHX1, CALU, GGCX</italic>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1-2</italic>
###xml 573 574 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 621 622 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 622 623 622 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 726 732 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 734 742 734 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 747 755 747 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3, PROC</italic>
###xml 757 776 757 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EPHX1, GGCX, ORM1-2</italic>
###xml 876 877 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 984 991 984 991 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 991 1067 991 1067 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53">Multiple regression model that explains 73% of the variance in warfarin dose</p>
###xml 991 1067 991 1067 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="53">Multiple regression model that explains 73% of the variance in warfarin dose</p></caption>
###xml 1067 1076 1067 1076 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Predictor</th>
###xml 1076 1079 1076 1079 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SNP</th>
###xml 1079 1080 1079 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1079 1086 1079 1086 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic>-Value</th>
###xml 1097 1098 1097 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1098 1099 1098 1099 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1086 1099 1086 1099 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Univariate <italic>R</italic><sup>2</sup></th>
###xml 1067 1099 1067 1099 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Predictor</th><th align="left">SNP</th><th align="left"><italic>P</italic>-Value</th><th align="left">Univariate <italic>R</italic><sup>2</sup></th></tr>
###xml 1067 1099 1067 1099 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Predictor</th><th align="left">SNP</th><th align="left"><italic>P</italic>-Value</th><th align="left">Univariate <italic>R</italic><sup>2</sup></th></tr></thead>
###xml 1099 1105 1099 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 1099 1105 1099 1105 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>VKORC1</italic></td>
###xml 1105 1114 1105 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs9923231</td>
###xml 1114 1121 1114 1121 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1121 1126 1121 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.317</td>
###xml 1099 1126 1099 1126 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>VKORC1</italic></td><td align="left">rs9923231</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.317</td></tr>
###xml 1126 1132 1126 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 1126 1132 1126 1132 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>CYP2C9</italic></td>
###xml 1143 1145 1143 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 1160 1162 1160 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 1132 1163 1132 1163 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1799853 (<italic>*2</italic>)&#160;+&#160;rs1057910 (<italic>*3</italic>)</td>
###xml 1163 1170 1163 1170 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1170 1175 1170 1175 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.159</td>
###xml 1126 1175 1126 1175 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1799853 (<italic>*2</italic>)&#160;+&#160;rs1057910 (<italic>*3</italic>)</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.159</td></tr>
###xml 1175 1178 1175 1178 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age</td>
###xml 1178 1178 1178 1178 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1178 1184 1178 1184 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0029</td>
###xml 1184 1189 1184 1189 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.092</td>
###xml 1175 1189 1175 1189 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age</td><td align="left"/><td char="." align="char">0.0029</td><td char="." align="char">0.092</td></tr>
###xml 1189 1193 1189 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 1189 1193 1189 1193 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>PROC</italic></td>
###xml 1193 1202 1193 1202 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2069919</td>
###xml 1202 1208 1202 1208 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0416</td>
###xml 1208 1213 1208 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.090</td>
###xml 1189 1213 1189 1213 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>PROC</italic></td><td align="left">rs2069919</td><td char="." align="char">0.0416</td><td char="." align="char">0.090</td></tr>
###xml 1213 1223 1213 1223 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Bodyweight</td>
###xml 1223 1223 1223 1223 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1223 1229 1223 1229 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0075</td>
###xml 1229 1234 1229 1234 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.057</td>
###xml 1213 1234 1213 1234 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Bodyweight</td><td align="left"/><td char="." align="char">0.0075</td><td char="." align="char">0.057</td></tr>
###xml 1234 1239 1234 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EPHX1</italic>
###xml 1234 1239 1234 1239 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>EPHX1</italic></td>
###xml 1239 1248 1239 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs4653436</td>
###xml 1248 1254 1248 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1016</td>
###xml 1254 1259 1254 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.048</td>
###xml 1234 1259 1234 1259 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>EPHX1</italic></td><td align="left">rs4653436</td><td char="." align="char">0.1016</td><td char="." align="char">0.048</td></tr>
###xml 1259 1270 1259 1270 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Interaction</td>
###xml 1270 1270 1270 1270 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1270 1276 1270 1276 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0878</td>
###xml 1276 1281 1276 1281 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.036</td>
###xml 1259 1281 1259 1281 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Interaction</td><td align="left"/><td char="." align="char">0.0878</td><td char="." align="char">0.036</td></tr>
###xml 1281 1285 1281 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX</italic>
###xml 1281 1285 1281 1285 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>GGCX</italic></td>
###xml 1285 1295 1285 1295 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs12714145</td>
###xml 1295 1301 1295 1301 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0260</td>
###xml 1301 1306 1301 1306 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.034</td>
###xml 1281 1306 1281 1306 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>GGCX</italic></td><td align="left">rs12714145</td><td char="." align="char">0.0260</td><td char="." align="char">0.034</td></tr>
###xml 1306 1310 1306 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1</italic>
###xml 1306 1310 1306 1310 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>ORM1</italic></td>
###xml 1310 1319 1310 1319 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1687390</td>
###xml 1319 1325 1319 1325 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0571</td>
###xml 1325 1330 1325 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.026</td>
###xml 1306 1330 1306 1330 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>ORM1</italic></td><td align="left">rs1687390</td><td char="." align="char">0.0571</td><td char="." align="char">0.026</td></tr>
###xml 1099 1330 1099 1330 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left"><italic>VKORC1</italic></td><td align="left">rs9923231</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.317</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1799853 (<italic>*2</italic>)&#160;+&#160;rs1057910 (<italic>*3</italic>)</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.159</td></tr><tr><td align="left">Age</td><td align="left"/><td char="." align="char">0.0029</td><td char="." align="char">0.092</td></tr><tr><td align="left"><italic>PROC</italic></td><td align="left">rs2069919</td><td char="." align="char">0.0416</td><td char="." align="char">0.090</td></tr><tr><td align="left">Bodyweight</td><td align="left"/><td char="." align="char">0.0075</td><td char="." align="char">0.057</td></tr><tr><td align="left"><italic>EPHX1</italic></td><td align="left">rs4653436</td><td char="." align="char">0.1016</td><td char="." align="char">0.048</td></tr><tr><td align="left">Interaction</td><td align="left"/><td char="." align="char">0.0878</td><td char="." align="char">0.036</td></tr><tr><td align="left"><italic>GGCX</italic></td><td align="left">rs12714145</td><td char="." align="char">0.0260</td><td char="." align="char">0.034</td></tr><tr><td align="left"><italic>ORM1</italic></td><td align="left">rs1687390</td><td char="." align="char">0.0571</td><td char="." align="char">0.026</td></tr></tbody>
###xml 1067 1330 1067 1330 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Predictor</th><th align="left">SNP</th><th align="left"><italic>P</italic>-Value</th><th align="left">Univariate <italic>R</italic><sup>2</sup></th></tr></thead><tbody><tr><td align="left"><italic>VKORC1</italic></td><td align="left">rs9923231</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.317</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1799853 (<italic>*2</italic>)&#160;+&#160;rs1057910 (<italic>*3</italic>)</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.159</td></tr><tr><td align="left">Age</td><td align="left"/><td char="." align="char">0.0029</td><td char="." align="char">0.092</td></tr><tr><td align="left"><italic>PROC</italic></td><td align="left">rs2069919</td><td char="." align="char">0.0416</td><td char="." align="char">0.090</td></tr><tr><td align="left">Bodyweight</td><td align="left"/><td char="." align="char">0.0075</td><td char="." align="char">0.057</td></tr><tr><td align="left"><italic>EPHX1</italic></td><td align="left">rs4653436</td><td char="." align="char">0.1016</td><td char="." align="char">0.048</td></tr><tr><td align="left">Interaction</td><td align="left"/><td char="." align="char">0.0878</td><td char="." align="char">0.036</td></tr><tr><td align="left"><italic>GGCX</italic></td><td align="left">rs12714145</td><td char="." align="char">0.0260</td><td char="." align="char">0.034</td></tr><tr><td align="left"><italic>ORM1</italic></td><td align="left">rs1687390</td><td char="." align="char">0.0571</td><td char="." align="char">0.026</td></tr></tbody></table>
###xml 1341 1342 1341 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1342 1343 1342 1343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1330 1378 1330 1378 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54">Univariate <italic>R</italic><sup>2</sup>-values are included for comparison</p>
###xml 1330 1378 1330 1378 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="54">Univariate <italic>R</italic><sup>2</sup>-values are included for comparison</p></table-wrap-foot>
###xml 984 1378 984 1378 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="53">Multiple regression model that explains 73% of the variance in warfarin dose</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Predictor</th><th align="left">SNP</th><th align="left"><italic>P</italic>-Value</th><th align="left">Univariate <italic>R</italic><sup>2</sup></th></tr></thead><tbody><tr><td align="left"><italic>VKORC1</italic></td><td align="left">rs9923231</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.317</td></tr><tr><td align="left"><italic>CYP2C9</italic></td><td align="left">rs1799853 (<italic>*2</italic>)&#160;+&#160;rs1057910 (<italic>*3</italic>)</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.159</td></tr><tr><td align="left">Age</td><td align="left"/><td char="." align="char">0.0029</td><td char="." align="char">0.092</td></tr><tr><td align="left"><italic>PROC</italic></td><td align="left">rs2069919</td><td char="." align="char">0.0416</td><td char="." align="char">0.090</td></tr><tr><td align="left">Bodyweight</td><td align="left"/><td char="." align="char">0.0075</td><td char="." align="char">0.057</td></tr><tr><td align="left"><italic>EPHX1</italic></td><td align="left">rs4653436</td><td char="." align="char">0.1016</td><td char="." align="char">0.048</td></tr><tr><td align="left">Interaction</td><td align="left"/><td char="." align="char">0.0878</td><td char="." align="char">0.036</td></tr><tr><td align="left"><italic>GGCX</italic></td><td align="left">rs12714145</td><td char="." align="char">0.0260</td><td char="." align="char">0.034</td></tr><tr><td align="left"><italic>ORM1</italic></td><td align="left">rs1687390</td><td char="." align="char">0.0571</td><td char="." align="char">0.026</td></tr></tbody></table><table-wrap-foot><p textid="54">Univariate <italic>R</italic><sup>2</sup>-values are included for comparison</p></table-wrap-foot></table-wrap>
###xml 156 163 <span type="species:ncbi:9606">patient</span>
###xml 974 982 <span type="species:ncbi:9606">patients</span>
To explore the potential of a warfarin dose prediction model, we combined the genes with the largest impact on warfarin dose (VKORC1, CYP2C9 and PROC) with patient characteristics (age, bodyweight, interaction with other drugs and indication for treatment) in a multiple regression model. This model explained 62% of the variance in dose. We then considered all nominally associated genes, VKORC1, CYP2C9, CYP2C19, CYP2C18, PROC, APOE, EPHX1, CALU, GGCX and ORM1-2 in a model, which explained 76% of the interindividual variance in warfarin dose. Variables with individual P-values above 0.2 and a low-explanatory value (R2) were subsequently removed from the model in a stepwise manner. We finally reached a model containing VKORC1, CYP2C9*2 and *3, PROC, EPHX1, GGCX, ORM1-2, age, bodyweight and drug interactions which explained 73% of the variance in warfarin dose (Table 4). However, this speculative model requires validation in a large independent sample of warfarin patients. Table 4Multiple regression model that explains 73% of the variance in warfarin dosePredictorSNPP-ValueUnivariate R2VKORC1rs9923231<0.00010.317CYP2C9rs1799853 (*2) + rs1057910 (*3)<0.00010.159Age0.00290.092PROCrs20699190.04160.090Bodyweight0.00750.057EPHX1rs46534360.10160.048Interaction0.08780.036GGCXrs127141450.02600.034ORM1rs16873900.05710.026Univariate R2-values are included for comparison
###end p 52
###begin p 53
Multiple regression model that explains 73% of the variance in warfarin dose
###end p 53
###begin p 54
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Univariate R2-values are included for comparison
###end p 54
###begin title 55
Conclusion
###end title 55
###begin p 56
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 8 38 8 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9, CYP2C19, CYP2C18, PROC</italic>
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 187 189 187 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 284 290 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 295 300 295 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C</italic>
###xml 434 440 434 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C</italic>
###xml 592 600 592 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 604 607 604 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3.</italic>
###xml 619 625 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 630 636 630 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 698 702 698 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 854 858 854 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">2003</xref>
###xml 1006 1010 1006 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 1144 1148 1144 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 1272 1279 1272 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE*E4</italic>
###xml 1338 1343 1338 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2005b</xref>
###xml 1408 1412 1408 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROC</italic>
###xml 1417 1421 1417 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 1370 1377 <span type="species:ncbi:9606">patient</span>
VKORC1, CYP2C9, CYP2C19, CYP2C18, PROC and APOE were all significantly associated with warfarin dose after correction for multiple testing. Three linked VKORC1 SNPs and the CYP2C9 allele *3 were the strongest genetic factors determining warfarin dose requirements. We fine mapped the VKORC1 and CYP2C regions in search of polymorphisms that might explain additional dose variance in our Swedish study population. However, none of the VKORC1 SNPs or haplotypes accounted for more dose variance than the three linked SNPs. Likewise, no CYP2C polymorphism contributed more to dose variance than CYP2C9*2 or *3. Apart from VKORC1 and CYP2C9, the most significant finding was the association of SNPs in PROC that reached gene-wise significance. Although factors II, VII and X have the strongest influence, it has been shown that protein C, the product of the PROC gene, has an effect on one of the outcome parameters of the current study, i.e. the prothrombin time (Watala et al. 2003). If genetic variation in PROC influences the prothrombin time, which in turn determines the required warfarin dose, it is not improbable that genetic variation in PROC plays a role for warfarin dose. Furthermore, as previously reported, CYP2C9 extensive metabolisers who were homozygous for APOE*E4 required higher warfarin doses than others (Kohnke et al. 2005b). Replication in a larger patient cohort will ascertain whether PROC and APOE are true determinants of warfarin dosing.
###end p 56
###begin p 57
###xml 149 155 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 157 165 157 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9*2</italic>
###xml 166 174 166 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3, PROC</italic>
###xml 216 227 216 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EPHX1, GGCX</italic>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ORM1-2</italic>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
With this systematic warfarin study, we can explain 62% of the variance in warfarin dose in Swedish patients by using a multiple regression model of VKORC1, CYP2C9*2/*3, PROC and non-genetic factors. The addition of EPHX1, GGCX and ORM1-2, to the model predicts an extra approximately10% of the variance. However, this model requires further validation in independent and larger samples, and will be tested in the WARG () cohort of 1,500 Swedish warfarin treated patients. Even so, this future model will only be applicable for patients of European ancestry, and similar studies need to be performed in other ethnic groups. When all common alleles contributing to warfarin response have been identified in the major ethnic groups, a comprehensive dose model that is applicable regardless of ethnicity can be developed. Dosing models may subsequently be translated into clinical guidelines for warfarin prescription, and could have a major impact on the safety and efficacy of warfarin.
###end p 57
###begin title 58
Electronic supplementary material
###end title 58
###begin p 59
Supplementary material
###end p 59
###begin p 60
###xml 382 394 <span type="species:ncbi:9606">participants</span>
The authors gratefully acknowledge Hakan Melhus and Qun-Ying Yue for initiating sample collection, Kristina Sorlin for extracting data from the medical records, Professor Munir Pirmohamed for helping to choose the candidate genes, David Vetrie for introduction to databases, Liz Sheridan for gene annotation, Ola Wallerman for technical assistance, and last but not least staff and participants of the study for their valuable contribution. This work was supported by the Wellcome Trust and the Swedish funding agencies: the Society of Medicine, Foundation for Strategic Research, Heart and Lung Foundation, and the Clinical Research Support (ALF) at Uppsala University. The sponsors had no role in the writing of this paper.
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk
###end article-title 62
###begin article-title 63
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements
###end article-title 63
###begin article-title 64
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Molecular analysis of Polish patients with factor VII deficiency
###end article-title 64
###begin article-title 65
The vitamin K-dependent carboxylase
###end article-title 65
###begin article-title 66
The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis
###end article-title 66
###begin article-title 67
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity
###end article-title 67
###begin article-title 68
Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane
###end article-title 68
###begin article-title 69
Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing
###end article-title 69
###begin article-title 70
###xml 13 18 <span type="species:ncbi:9606">human</span>
Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor
###end article-title 70
###begin article-title 71
A simple correction for multiple comparisons in interval mapping genome scans
###end article-title 71
###begin article-title 72
Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases
###end article-title 72
###begin article-title 73
Pharmacogenetics of oral anticoagulants
###end article-title 73
###begin article-title 74
Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin
###end article-title 74
###begin article-title 75
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
###end article-title 75
###begin article-title 76
Pedigree disequilibrium tests for multilocus haplotypes
###end article-title 76
###begin article-title 77
###xml 41 46 <span type="species:ncbi:9606">human</span>
The structure of haplotype blocks in the human genome
###end article-title 77
###begin article-title 78
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin
###end article-title 78
###begin article-title 79
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation
###end article-title 79
###begin article-title 80
###xml 20 25 <span type="species:ncbi:9606">human</span>
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
###end article-title 80
###begin article-title 81
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism
###end article-title 81
###begin article-title 82
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human P450 metabolism of warfarin
###end article-title 82
###begin article-title 83
###xml 34 40 <span type="species:ncbi:9606">humans</span>
Transport of vitamin K to bone in humans
###end article-title 83
###begin article-title 84
Apolipoprotein E (APOE) and warfarin dosing in an Italian population
###end article-title 84
###begin article-title 85
Warfarin dose related to apolipoprotein E (APOE) genotype
###end article-title 85
###begin article-title 86
###xml 24 31 <span type="species:ncbi:9606">patient</span>
Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity
###end article-title 86
###begin article-title 87
Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention
###end article-title 87
###begin article-title 88
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation
###end article-title 88
###begin article-title 89
Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population
###end article-title 89
###begin article-title 90
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions
###end article-title 90
###begin article-title 91
A permutation procedure for the haplotype method for identification of disease-predisposing variants
###end article-title 91
###begin article-title 92
Identification of the gene for vitamin K epoxide reductase
###end article-title 92
###begin article-title 93
Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9
###end article-title 93
###begin article-title 94
Interindividual variability in sensitivity to warfarin- Nature or nurture?
###end article-title 94
###begin article-title 95
Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles
###end article-title 95
###begin article-title 96
A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other
###end article-title 96
###begin article-title 97
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 92 97 <span type="species:ncbi:9606">human</span>
A comparative study of the interaction of warfarin with human alpha 1-acid glycoprotein and human albumin
###end article-title 97
###begin article-title 98
Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations
###end article-title 98
###begin article-title 99
###xml 26 32 <span type="species:ncbi:9606">humans</span>
Linkage disequilibrium in humans: models and data
###end article-title 99
###begin article-title 100
###xml 29 34 <span type="species:ncbi:9606">human</span>
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions
###end article-title 100
###begin article-title 101
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
###end article-title 101
###begin article-title 102
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
###end article-title 102
###begin article-title 103
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
###end article-title 103
###begin article-title 104
###xml 71 79 <span type="species:ncbi:9606">patients</span>
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis
###end article-title 104
###begin article-title 105
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis
###end article-title 105
###begin article-title 106
###xml 57 64 <span type="species:ncbi:9606">patient</span>
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
###end article-title 106
###begin article-title 107
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
###end article-title 107
###begin article-title 108
Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity
###end article-title 108
###begin article-title 109
Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk
###end article-title 109
###begin article-title 110
###xml 68 73 <span type="species:ncbi:9606">human</span>
The predictice nature of high throughput toxicity screening using a human hepatocyte cell line
###end article-title 110
###begin article-title 111
Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin
###end article-title 111
###begin article-title 112
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
###end article-title 112
###begin article-title 113
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
###end article-title 113
###begin article-title 114
Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX
###end article-title 114
###begin article-title 115
Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin
###end article-title 115
###begin article-title 116
###xml 113 120 <span type="species:ncbi:9606">patient</span>
Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
###end article-title 116
###begin article-title 117
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants
###end article-title 117
###begin article-title 118
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
###end article-title 118
###begin article-title 119
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
###end article-title 119
###begin article-title 120
###xml 154 158 <span type="species:ncbi:10116">rats</span>
The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats
###end article-title 120
###begin article-title 121
Vitamin K-dependent carboxylation. Evidence that at least two microsomal dehydrogenases reduce vitamin K1 to support carboxylation
###end article-title 121
###begin article-title 122
###xml 61 64 <span type="species:ncbi:10116">rat</span>
A molecular mechanism for genetic warfarin resistance in the rat
###end article-title 122
###begin article-title 123
###xml 177 185 <span type="species:ncbi:9606">patients</span>
Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients
###end article-title 123
###begin article-title 124
###xml 54 59 <span type="species:ncbi:9606">human</span>
Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase
###end article-title 124
###begin article-title 125
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
###end article-title 125
###begin article-title 126
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe
###end article-title 126
###begin title 127
Abbreviations
###end title 127
###begin p 128
ATP-binding cassette transporter B1 gene, P-glycoprotein gene or MDR1
###end p 128
###begin p 129
Apolipoprotein E
###end p 129
###begin p 130
Calumenin gene
###end p 130
###begin p 131
Constitutive androstane receptor
###end p 131
###begin p 132
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
Cytochrome P450 1A1
###end p 132
###begin p 133
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
Cytochrome P450 1A2
###end p 133
###begin p 134
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
Cytochrome P450 2A6
###end p 134
###begin p 135
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
Cytochrome P450 2C18
###end p 135
###begin p 136
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
Cytochrome P450 2C19
###end p 136
###begin p 137
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
Cytochrome P450 2C8
###end p 137
###begin p 138
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
Cytochrome P450 2C9
###end p 138
###begin p 139
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
Cytochrome P450 3A4
###end p 139
###begin p 140
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
Cytochrome P450 3A5
###end p 140
###begin p 141
Epoxide hydrolase 1, microsomal gene
###end p 141
###begin p 142
Coagulation factor II gene or prothrombin gene
###end p 142
###begin p 143
Coagulation factor V gene
###end p 143
###begin p 144
Coagulation factor VII gene
###end p 144
###begin p 145
Coagulation factor IX gene
###end p 145
###begin p 146
Coagulation factor X gene
###end p 146
###begin p 147
Coagulation factor II or prothrombin
###end p 147
###begin p 148
Coagulation factor II activated or thrombin
###end p 148
###begin p 149
Coagulation factor IX
###end p 149
###begin p 150
Coagulation factor IX activated
###end p 150
###begin p 151
Coagulation factor V
###end p 151
###begin p 152
Coagulation factor VII
###end p 152
###begin p 153
Coagulation factor VII activated
###end p 153
###begin p 154
Coagulation factor X
###end p 154
###begin p 155
Coagulation factor X activated
###end p 155
###begin p 156
Growth-arrest specific 6
###end p 156
###begin p 157
Gamma-glutamyl carboxylase gene
###end p 157
###begin p 158
Multidrug resistance gene 1, P-glycoprotein gene or ABCB1
###end p 158
###begin p 159
NAD(P)H dehydrogenase, quinone 1 gene
###end p 159
###begin p 160
Pregnane X receptor gene
###end p 160
###begin p 161
Constitutive androstane receptor gene
###end p 161
###begin p 162
Orosomucoid 1 gene or Alpha-1-acid glycoprotein 1 gene
###end p 162
###begin p 163
Orosomucoid 2 gene or Alpha-1-acid glycoprotein 2 gene
###end p 163
###begin p 164
Polymerase chain reaction
###end p 164
###begin p 165
Protein C gene
###end p 165
###begin p 166
Protein S gene
###end p 166
###begin p 167
Protein Z gene
###end p 167
###begin p 168
Prothrombin time international normalised ratio
###end p 168
###begin p 169
Pregnane X receptor
###end p 169
###begin p 170
Anti-thrombin III gene
###end p 170
###begin p 171
Small interfering ribonucleic acid
###end p 171
###begin p 172
Single nucleotide polymorphism
###end p 172
###begin p 173
Untranslated region
###end p 173
###begin p 174
Vitamin K epoxide reductase complex subunit 1 gene
###end p 174
###begin p 175
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 175
###begin p 176
Supplementary material is available in the online version of this article at  and is accessible for authorized users.
###end p 176

